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The liver has a major role in the metabolism of cholesterol, being
the main site of lipoprotein assembly and degradation and the only
tissue where the metabolism of cholesterol to bile acids occurs.
This provides the major pathway for the removal of cholesterol from
the body.
The results described in this thesis concern the use of specific
enzyme inhibitors (58-035, Azacholesterol, Mevinolin) to determine
the intracellular use of different sources of cholesterol in
monolayers of rat hepatocytes. In particular, the fates of newly
synthesized cholesterol from mevalonic acid and cholesterol derived
from HDL2 were investigated.
Incubation of hepatocyte monolayers with 58-035 resulted in the
inhibition of esterification. In the presence of mevalonic acid as
a cholesterol source, 58-035 stimulated bile acid synthesis.
Azacholesterol inhibited bile acid synthesis, had no effect on
cholesterol synthesis, and in the presence of mevalonic acid,
stimulated secretion of cholesterol by the hepatocytes; it had no
effect on cholesterol esterification. Mevinolin inhibited
cholesterol synthesis and as a result inhibited esterification.
HDL2, in the presence of mevinolin, was used as a cholesterol
source. It stimulated bile acid synthesis and cholesterol
esterification. Addition of 58-035 to the system resulted in the
inhibition of both esterification and bile acid synthesis. Overall,
the results indicated that different intracllular pools of free
cholesterol exist and that the inter-relationships of these pools
give a complex pattern of flux of intracellular cholesterol between
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Cholesterol, a necessary component of all mammalian tissues, has
critical roles as a structural constituent of all membranes and
lipoproteins and as an Immediate precursor of steroid hormones,
vitamins and bile acids. To meet these demands, a series of
synthetic, transport and regulatory mechanisms have evolved to
ensure a sufficient supply of cholesterol to the tissues. The total
body pool of cholesterol is derived from two sources: dietary and
synthetic. De novo synthesis of cholesterol can occur in all
nucleated mammalian cell types; however most synthesis occurs in the
liver and small intestine (Andersen and Dietschy, 1979; Dietschy and
Wilson, 1970; Turleyfiial., 1981).
The combination of dietary uptake and de novo synthesis usually
supplies more cholesterol than is utilized during normal metabolic
turnover (Turley and Dietschy, 1982). It is thus important that
regulatory mechanisms exist not only to ensure adequate provision,
but also to prevent accumulation of cholesterol. For some time, it
has been established that high levels of plasma cholesterol
correlate positively with the incidence of ischaemic heart disease
(Lipid Research Clinics Coronary Primary Prevention Trial Results,
1984), which indicates the seriousness of excess accumulation. The
problem is that mammalian tissues are not capable of degrading the
sterol nucleus. This knowledge has provoked extensive investigation
into possible mechanisms of cholesterol removal from the body.
Particularly, the synthesis and excretion of b11 e acids and the
removal of plasma lipoproteins from the circulation have been
closely studied.
As mentioned, the liver is a primary site of cholesterol synthesis;
it is also a major site for the synthesis, uptake and degradation of
plasma lipoproteins, and the only site of bile acid synthesis and
excretion, which provides the major route for cholesterol removal
from the body. Thus, the liver has a central role in the control of
the total body pool of sterols.
2
1.2 Cholesterol Synthesis
One of the major sources of total body cholesterol is de novo
synthesis. In the rat, cholesterol synthesis by the major organs
and tissues has been studied, and it has been demonstrated that the
liver accounts for most of the total body synthesis (Turley si &1.,
1981). The control and regulation of its synthesis has been shown
to be very complex, and that the uptake of cholesterol via a
lipoprotein carrier affects the rate of hepatic cholesterol
synthesis (Andersen and Dietschy, 1977a). Chylomicron remnant or
LDL uptake has been shown to suppress hepatic cholesterol synthesis,
whilst HDL had no effect (Andersen and Dietschy, 1977b). The rate
of cholesterol synthesis varies widely according to the stimuli.
The formation of cholesterol begins with ^kt^Co^and proceeds
through approximately 20 steps. The rate limiting step of its
synthesis is the conversion of 3-hydroxy-3-methyl glutaryl coenzyme
A (HMG-CoA) to mevalonic acid. The reaction is catalyzed by the
enzyme HMG-CoA reductase, an enzyme that has been shown to undergo
activation - inactivation by a dephosphorylation - phosphorylation
regulatory mechanism (Nordstrom si &1., 1977; Gibson and Ingebritsen,
1978; Beg si si., 1978). Mevalonic acid undergoes a series of
condensation reactions to form squalene, which is cyclized to
lanosterol. The latter is converted to cholesterol via a series of
steps that modify the ring and side chain structure of the molecule.
The control and regulation of its synthesis has been shown to be
very complex (Andersen and Dietschy 1977a). A rise in hepatic
cholesterol exerts feedback inhibition of cholesterol synthesis, and
the amount of HMG-CoA reductase is reduced by a high intracellular
concentration of cholesterol. The precise mechanism by which
cholesterol exerts this feedback control is not known, but some
investigations have suggested that the regulating sterol is not
cholesterol but an oxidation product such as 26-hydroxycholesterol
(Kandutsch, 1978). Further to this, it has been shown that the
uptake of cholesterol in the form of lipoproteins affects the rate
of hepatic cholesterol synthesis. Chlyomicron remnants of LDL were
shown to suppress hepatic cholesterol synthesis whilst HDL had no
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effect (Andersen and Dietschy 1977b). Furthermore, the rate of
cholesterol synthesis has been shown very widely depending upon the
stimuli (Andersen and Dietschy, 1977a and 1977b; Koelz £± &!_. 1982;
Grundy, 1986)
A review by Turley and Dietschy (1982) outlines the rates of
cholesterol synthesis 1n the liver and Its contribution to whole
body cholesterol in a number of species.
1.3 The Bile Acids
B1le acids are C-24 to C-28 carboxylic acids with a steroid nucleus
derived from cholesterol, containing hydroxylic substituents and all
or part of the side chain of 56 - cholestane. Nearly all conjugated
bile acids have 24 carbon atoms with the basic structure of 56 -
cholan-24-oic acid (figure 1.1). This type is the major one found
in man and experimental animals. There are, however, C-27 bile
alcohol sulphates to be found in lower vertebrates and taurine
conjugates of C-27 and C-28 bile acids have been isolated from
reptiles and amphibians (Haslewood, 1978).
The hydroxyl substituents of bile acids usually occur at C-3, C-7
and/or C-12 on the steroid nucleus. The two major bile acids found
in most species are 3a, 7a 12a trihydroxy - 56 cholan - 24 oic acid
(cholic acid); 3a, 7a di hydroxy - 56 cholan - 24 oic acid
(chenodeoxycholic acid). There is a good deal of species variation
that occurs. For instance, in man another major bile acid is
deoxycholic acid, with small amounts of 1ithocholic acid also being
synthesized; in rat, B-muricholic acid is one of the primary bile
acids synthesized.
Free, or unconjugated, bile acids are not usually present in the
bile, but are enzymatically conjugated to glycine or taurine by
peptide linkage at the C.24 position. As there is only one enzyme
in the liver responsible for conjugation, the amount of glycine or
taurine conjugated is dependent upon the substrate supply and the
substrates differing affinities for the enzyme (Vessey, 1978).
Figure 1.1 Chemical structures of (a) 5a-cho1estane; (b) 5B-cholan-
24-oic acid; (c) cholic acid; (d) chenodeoxycholic acid; (e) lithocholic
acid and (f) g-muricholic acid.
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In vertebrates, formation of bile acids occurs in the liver via a
series of reactions, initiated by the 7a - hydroxylation of
cholesterol, (Danielsson and Sjovall, 1975; Salen and Shefer,
1983). They are then conjugated, secreted into the bile cannaliculi
and thence to the biliary tract and the intestinal lumen. Once into
the intestinal lumen, the bile acids facilitate the formation of
the micellar phase that is necessary for the absorption of
cholesterol, fat-soluble vitamins and the products of triglyceride
hydrolysis formed during fat digestion.
In mammalian species, the pathway of bile acid synthesis is
essentially the same (Figure 1.2), but there are considerable
variations in the end products (Elliot and Hyde, 1971). As
mentioned, in most species cholic and chenodeoxycholic acids are the
major bile acids produced; however, in rats, chenodeoxycholic acid
can be further metablised to a - and 6-muricholic acids (Mahawold si
Si-, 1957; Matschiner si si., 1971; Voight st si-, 1968).
The first and rate controlling step 1n bile acid synthesis is the 7a
hydroxylation of cholesterol to form 7a-hydroxycholesterol. The
enzyme that catalyzes this step, cholesterol 7a-hydroxlyase, is
found in the endoplasmic reticulum, and requires oxygen, NADPH and a
thermostable co-factor (Scholan and Boyd, 1968; Boyd si si., 1969;
Myant and Mitropoulos, 1977). The reaction is dependent upon a
minor form of cytochrome P-450 (Danielsson and Hikvall, 1981).
Further metabolism of 7a-hydroxycholesterol involves the oxidation
of the 3 B-hydroxyl group and isomerization of the double bond from
C-5,6 to C-4,5, producing 7a-hydroxy-4-cholesten-3-one. This the
final intermediate common to both cholic and chenodeoxycholic acid
synthesis. This ketone can be 12a-hydroxylated to produce 7a,
12a-dihydroxy-4-cholesten-3-one, which then undergoes reduction of
the double bond and C-3 ketone to form 5B-cholestane-3a, 7a,
12a-triol. For chenodeoxycholic acid synthesis, the
7a-hydroxy-4-cholesten-3-one is reduced to produce 5B-cholestone-3a,
7a diol. Both the d1ol and the triol undergo degradation of the
cholestane side chain to produce chenodeoxycholic and cholic acid
Figure 1.2 The biosynthetic pathway of bile acids.
Structures: I) Cholesterol; II) 7a-hydroxycholesterol; III)
7a-hydroxy-4-cholesten-3-one; IV) 7a,12a-dihydroxy-4-cholesten-3-one;
V) 58-cholestane-3a,7a,12a,26-tetrol; VII) cholic acid; VIII)
5B-cholestane-3a,7a-diol; IX) 5G-cholestane-3a,7a,26-triol; X)
chenodeoxycholic acid; XI) a-muricholic acid XII) G-muricholic acid
Enzymes: a) Cholesterol 7a-hydroxylase; b) 7a-hydroxy-4-
cholesten-3-one 12a-hydroxylase; c) 26-hydroxylase; d) chenodeoxy¬





respectively. In the rat, chenodeoxycholic acid is further
hydroxylated to yield a- and 6-mur1cholic acid.
Two pathways have been proposed for the degradation of the
cholestane side chain. They differ in the intracellular site of the
initial hydroxylation. They are discussed below and outlined in
Figure 1.3 for the synthesis of chollc acid.
The mitochondrial fraction of both rat and human liver contains the
enzyme 26-hydroxylase (Bjorkhem si al., 1975) which can convert
5B-cholestane-3a, 7a, 12a triol to 5B cholestane - 3a, 7a, 12a,
26-tetrol. The tetrol is then oxidized to 3a, 7a,
l2a-tr1hydroxy-56Tcholestane-26-oic acid (THCA) by the cytosol.
This is followed by hydroxylation at C-24, yielding varanic acid,
and then oxidized to shorten the side chain and yield chollc acid.
The alternative to this pathway, 25 hydroxylation, occurs in both
rat and human liver (Shefer si &1., 1975). The first step is the
25-hydroxylation of 5B-cholestane - 3a, 7a, 12a-triol to give 5B
cholestane - 3a, 7a, 12a, 25 tetrol. The reaction is catalyzed by
a microsomal enzyme system and is followed by 24-hydroxylation of
the 5B-cholestane tetrol to yield 58-cholestane - 3a, 7a, 12a, 24,
25 - pentol. This is then oxidized to yield 3a, 7a, 12a, 25 -
tetrahydroxy-5B-cholestane-24-one (Shefer si al_., 1982), which is
then cleared by cytosolic enzymes to yield cholic acid and acetone.
After synthesis and secretion, bile acids are highly conserved.
This occurs via the enterohepatic circulation and 95% of the bile
salts that enter the duodenum in the normal state are recycled. To
facilitate this, a specific transport system exists in the terminal
portion of the small intestine (Dietschy, 1968). The 7a-hydroxylase
enzyme system is sensitive to factors or events that modify the
enterohepatic circulation. When bile acids are prevented from
returning to the liver, the rate of bile acid synthesis increases.
From this, the concept of negative feedback regulation of bile acid
synthesis by bile acids was developed. It has been shown that the
activity of cholesterol 7a-hydroxylase increases in parallel with
bile acid synthesis and is affected by the levels of bile acids in
the enterohepatic circulation (Myant and Mitropoulos, 1977).
Figure 1.3 The 26-hydroxylase (a) and the 25-hydroxylase (b)
pathways for the degradation of the side chain of 5B-cholestane-3a,7a
12a-triol (I) to form cholic acid (VII).
Structures: II) 58-cholestane-3a,7a,12a,26-tetroi; III) 3a,7a,12a-
trihydroxy-58-cholestan-26-oic acid; IV) Vasanic acid; V) 56-




Recently, studies with microsomal preparations have produced
evidence that cholesterol 7a-hydroxylase exists in two forms, which
are interconverted by cytosolic factors (Goodwin ei ah, 1982; Kwok
£l 41., 1981a, Kwok ei &]_., 1983). These factors may be a protein
kinase and phosphatase, which have been proposed to regulate the
enzyme by a phosphorylation (active form) - dephosphorylation
(inactive form) mechanism (Sanghvi ei al., 1981). Acyl - CoA
cholesterol acyltransferase (ACAT), which utilizes cholesterol as a
substrate, may be regulated in this manner, whilst
3-hydroxy-3-methyl-glutaryl CoA reductase (HMG-CoA reductase) is
inhibited in the phosphorylated form. It has been postulated that
short-term regulation of the concentration of unesterified
cholesterol may be by coordinate control of these three enzymes by
reversible phosphorylations (Seal 1 en and Sanghvi, 1983).
Other investigators dispute this hypothesis, denying that
cholesterol 7a-hydroxylase activity is modulated by phosphorylation
- dephosphorylation (Danielsson ei al-, 1980; Danielsson at aj..,
1984). Berglund it &!•, (1986), have shown that under conditions
favourable for phosphorylation - dephosphorylation, cholesterol
7a-hydroxylase activity was not affected. Under similar conditions,
hepatic HMG-CoA reductase activity was modulated by phosphorylation
- dephosphorylation as shown by other workers (Nordstrom et al-,
1977; Gibson and Ingebritsen, 1978; Beg et al., 1978). Certainly
there is no clear resolution to this question at this time.
Considering that all the work so far deals with in vitro experimental
systems which vary in design, no conclusions can yet be drawn as to
what is occurring in vivo.
Another mechanism for the regulation of bile acid synthesis is
through control of substrate availability. Newly synthesized
cholesterol, preformed cholesterol existing in various functional
pools within the cell and extracellular cholesterol in the form of
plasma lipoproteins containing cholesterol arising from the
d1et(chylomicron remnants) or from other tissues in the body (LDL
and HDL), are possible sources of cholesterol for bile acid
synthesis. It has been shown that the preferred substrate for bile
acid synthesis is newly synthesized cholesterol (Schwartz et el-.
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1975; Bjorkhem and Lewenhaupt, 1979). It has also been shown that
the preferred substrate for the synthesis of 7a-hydroxycholesterol
is newly synthesized cholesterol (Myant and Mitropoulos, 1977;
Bjorkhem and Danielsson, 1975; Ogura et al_., 1976). These
experiments do not state that newly synthesised cholesterol is the
only substrate for bile acid synthesis, only that it is preferred;
nor does it mean that most of the bile acids are synthesised from
this source. In rats, it has been reported that only 25% of the
bile acids are derived from newly synthesized cholesterol, the
remaining 75% being derived from preformed cholesterol (Long et al.,
1978). The contribution to bile acid synthesis of these different
sources can change. A bile fistula was shown to increase the
contribution of the newly synthesised cholesterol, whilst the mass
of the alternate substrate pool remained unchanged (Long e± al.,
1978; Stange et al., 1985). The fistula interrupts the
enterohepatic circulation and stimulates bile acid synthesis. These
results reflect the livers' ability to alter the rate of cholesterol
synthesis to meet the increase in bile acid synthesis. (Koelz at
al., 1982). Kempen et al (1983), in experiments on the incorporation
of tritiated water into cholesterol and bile acids by isolated
hepatocytes from cholestyramine - fed rats, have estimated that
during the first hour of incubation all the bile acid is formed from
pre-existing cholesterol. After this time, the rate of bile acid
synthesis dropped and newly synthesized cholesterol became more
important as a substrate, probably because the sources of preformed
cholesterol available have been exhausted.
Other investigations have looked at the possible preferential
utilization of cholesterol from a particular lipoprotein source.
Radioactive cholesterol in serum lipoproteins can be converted to
bile acids when administered in vivo (Halloran et a]_., 1978, Miller
et al., 1982, Price et al., 1985) and therefore contribute to total
bile acid synthesis. High-density lipoprotein (HDL) is a better
precursor for bile acids than low-density lipoproteins; both in man
(Halloran et al., 1978, Price et al., 1985) and the rat (Miller et
al-, 1982). Recent work with cultured rat hepatocytes has found
that bile acid synthesis and secretion was increased when the
hepatocyte cholesterol pool was increased , either by addition of
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mevalonic acid or lipoprotein fractions to the culture medium, or by
feeding a cholesterol-rich diet (Davies et al-, 1983b).
Interestingly, bile acids did not have a direct inhibitory effect on
bile acid synthesis in this experimental system (Davis et al.,
1983a). This conflicts with the results of in vivo work that have
suggested bile acids regulate their own synthesis by a negative
feedback mechanism. It is possible, however, that an intestinally
derived factor or metabolite may be required for this effect.
Further investigations into the existence of substrate pools for the
synthesis of bile acids have suggested that individual bile acids
may be derived from distinct substrate pools. A number of
investigators have reported that cholic acid and chenodeoxycholic
acid (Mitropoulos £± al-, 1974; Norman and Norum, 1976; Bjorkhem and
Lewenhaupt, 1979; Long et al., 1978) or cholic acid and B-muricholic
acid (Kempen et al., 1983, Stange et al., 1985) are all derived from
separate substrate pools.
1.4 The Plasma Lipoproteins
The plasma lipoproteins are water-soluble macromolecules
(pseudomicellar particles) representing complexes of lipids
(triglycerides, cholesterol and phospholipids) and one or more
proteins referred to as apoproteins. The lipoproteins, of which
there are five main classes, function to transport the afore
mentioned lipids in the plasma. Certain of them act as vehicles for
lipids entering the plasma from the intestine. Others function to
transport lipids from one tissue to another, where the lipids can be
used as structural components of the cell (e.g. cholesterol), or as
precursors of tissue product (e.g. cholesterol for steroid
hormones). Further to this, lipoproteins transport lipids to
specific organs for storage (triglycerides to adipocytes) or for
excretion from the body (cholesterol to the liver).
The five main classes of lipoproteins float within different density
ranges under ultracentrifugation (Havel et al., 1955). These
classes are chlyomicrons, very low density lipoproteins (VLDL),
intermediate density lipoproteins (IDL), low density lipoproteins
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(LDL), and high density lipoproteins (HDL) (Table 1.1). They vary
by their chemical composition as well as their physical properties
(Table 1.1). The density ranges chosen for lipoprotein isolation
are based on those of human plasma lipoproteins, a situation that
does not apply to all species. In the rat, isolation of LDL and IDL
is difficult (Chapman, 1980); the conventional density range of
1.006-1.063 g ml-1, in which both LDL and IDL appear, is
contaminated with apo E (Innerarity et al., 1980a).
This has been shown to be caused by an HDL subtraction rich in apo
E. This is important because it is the chemical composition, and in
particular the apoprotein content of a lipoprotein molecule that
determines its function and subsequent catabolism.
1.4.1 The Lipoprotein Classes and their Metabolism
It was thought that plasma lipoproteins were synthesized by the
liver and small intestine only. Evidence supports the idea that
intestinal cells and hepatocytes are the source of virtually all the
circulating chylomicrons and VLDL (Havel et al., 1980). Nascent HDL
has been found primarily in hepatic perfusates in several mammals
(Hamilton, 1984), and it appears that this is the major site of HDL
production, although in the rat some HDL is synthesized in the
intestine (Green and Glickman, 1981; Forester, ei al., 1983).
Recently, cells other than those of the small intestine and liver
have been shown to synthesize some of the apolipoproteins.
Apolipoprotein E is synthesized by the kidney and adrenal glands in
the human (Blue £t al., 1983), and the mRNA of apolipoprotein E has
been found in the liver, adrenal glands, brain and spleen of other
animals (Elshourbagy et al., 1985; Newman et al., 1984). Apo E is
also secreted from mouse and human macrophages under certain
conditions, such as cholesterol loading (Basu et al., 1982). The
form in which this protein is secreted from these cells is not yet
known nor has its function been determined.
(a) Chylomicrons
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pre-B a a




0.95-1.00610-80000K2 563 1.006-1.0192300K 1.063-1.0853 0K 1.085-1.21075K
23.50 28.5 40.5
5.02 2.5418 27.581 25.5832 26.03.57
Table1.1 PhysicalandchemicpropertiesofRPlasmalipoprot ins.1)abbreviations:TG-trigly eride ;CE cholesterylest r;FC-frcholest ol;PL-phospholipids.
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and secreted into the intestinal lymph during absorption of dietary
fat. From here they are transported into the plasma compartment via
the thoracic duct, and subsequently catabolised (Green and Glickman,
1982). The apoprotein constituents of plasma chylomicrons are
apoproteins A-I (apo A-I), A-IV (apo A-IV), B (apo B), C (apo C) and
E (apo E).
The C apoliproteins are represented by three low molecular weight
apoproteins C-I, C-II, C—III. These proteins share the common
property of redistributing among lipoprotein classes (Nestel &
Fidge, 1982). These apoproteins preferentially redistribute to the
surface of the triglyceride-rich chylomicrons during the initial
synthesis of the lipoprotein molecule. As the triglyceride core of
the chlyomicron is depleted during its catabolism, excess surface
components are generated and the C apolipoproteins are transferred
to HDL (Mahley et a]_., 1984). Individually, they have other
functions. Large quantities of apo C-III relative to apo C inhibits
the uptake of chlyomicron particles by the liver, thus allowing
catabolism of dietary triglycerides (Redgrave, 1970). Apo C-II
activates the enzyme lipoprotein lipase. LPL is bound to the
capillary endothelium and is found in most extrahepatic tissues. It
acts to hydrolyse the core triglyceride, releasing mono - and
diacylglycerol and fatty acids. The mono - and diacylglycerol are
either delivered to muscle and adipose tissue or further hydrolysed
to fatty acids in the plasma. The fatty acids so released are
picked up by albumin and transported to the liver. As the
triglyceride core is depleted, surface compounds "bud-off", forming
vesicles consisting of free cholesterol, phospholipid and
apoproteins A-I, A-IV and C. These components are transferred to
nascent HDL (Mahley et al., 1984), resulting in the formation of a
cholesteryl ester rich particle termed a chylomicron remnant. The
protein of the particle consists apo B and E, which results in the
uptake of the particle by the hepatic apo E receptor (Havel, 1984;
Cooper, 1985). The uptake of the chlyomicron remnants results in
the protein and cholesteryl ester moieties entering into lysosomes
where they are hydrolysed (van Dyke et al., 1985 and Jost-Vu, 1986).
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(b) Very Low Density Lipoprotein (VLDL)
Very low density lipoproteins are synthesized by both the liver and
small intestine. Intestinal VLDL functions in a similar way to
chylomicrons, transporting dietary lipid into the plasma.
Quantitatively, the chylomicrons are more important than the VLDL in
terms of the absorption of dietary lipid. The nascent particles, on
entering the plasma, transfer apo A-I and A-IV to HDL and acquire
apo-E and C from HDL (Green et al., 1979; Green and Glickman,
1981). These exchanges produce the apoprotein profile of VLDL
normally found in the plasma (Havel et al., 1980). In the rat,
newly secreted VLDL contains a large amount of cholesteryl esters,
synthesized by hepatic ACAT (Faergeman and Havel, 1975); however, it
acquires little in the plasma due to the low cholesteryl
ester/triglyceride transfer activity (Barter and Lally, 1978; Barter
et al., 1982; Tall, 1986). In humans the situation is different;
ACAT activity is low and cholesteryl ester/triglyceride transfer
activity is high, thus VLDL acquires cholesteryl esters from HDL
synthesized in the plasma by lecithin: cholesterol acyl transferase
(LCAT) (Tall, 1986).
The initial step of VLDL metabolism is basically the same as for
chylomicrons - binding to endothelial lipoprotein lipase, followed
by hydrolysis of the bulk of the triglycerides. As with
chlyomicrons, phospholipids and apo C apoproteins are transferred to
HDL as hydrolysis proceeds; thus the products of LPL action, VLDL
remnants, are depleted of triglycerides, phospholipids and C
apoproteins, but retain apo B and E (Mjos et al., 1975; Havel,
1984). This hydrolysis results in delivery of mono - and
diacylglycerol to the peripheral tissues. Surface components are
then transferred from VLDL to HDL in the same manner as occurs with
chylomicrons (Tall and Small, 1980, Gotto et al-, 1986). The
transfer of apoproteins A-I, A-IV and C, phospholipid and free
cholesterol from VLDL to HDL produces VLDL remnants. In many
species, most of the VLDL remnants are taken up by receptor-mediated
endocytosis (Havel, 1984). The rat in particular removes the
remnants from the circulation quite rapidly, allowing only 3% of the
remnants to be converted to LDL (Faergeman and Havel, 1975). In







































































































(Havel, 1984). Small VLDL yield small remnants, which are more
likely to form LDL than larger remnants, whereas large VLDL is
thought to produce large remnants that are more likely to be removed
quickly by the liver, (Stalenhoef fit al_., 1984; Packard fit al-»
1984). The formation of LDL from VLDL occurs with further loss of
triglycerides phospholipids and apo E, leaving only Apo B-100 in the
LDL particles. In species with active cholesteryl
ester/triglyceride transfer activity, processing of remnants to form
LDL may be followed by redistribution of cholesteryl esters to
larger paticles in exchange for triglycerides (Deckelbaum et al.,
1982).
(c) Low Density Lipoproteins and Intermediate Density Lipoproteins
Both VLDL remnants and LDL, which contain apo B-100, are removed
from the blood by interaction with LDL receptors (Goldstein e± al.,
1983), also referred to as apo B/E receptors. VLDL remnants are
almost entirely removed by the liver, where efficient interaction
between apo E and hepatic LDL receptors occurs (Havel, 1984). LDL,
on the other hand, are removed less efficiently than VLDL through
binding by the receptors to apo B-100, and are thus taken up by
extrahepatic tissues that contain LDL receptors. From this, it can
be seen that LDL functions to transport cholesterol to extrahepatic
tissues, although the liver also contributes to the catabolism of
LDL (Pittman fit al., 1979; Attie et al., 1982; Stange and Dietschy,
1984).
In general,LDL uptake by extrahepatic tissues results in the
inhibition of HMG -CoA reductase and stimulation of ACAT, thus
reducing synthesis of cholesterol, and increasing the esterification
of the cholesterol taken up by the tissue (Goldstein and Brown,
1974; Brown fit al.. 1975). LDL uptake occurs by both receptor
(mentioned above) and non-receptor pathways, which will be discussed
later.
IDL represents an intermediate in the conversion of VLDL to LDL by
lipoprotein lipase. It contains relatively less triglyceride and
cholesteryl ester compared to VLDL, although VLDL may contain
particles that are functionally equivalent to IDL.
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(d) High Density Lipoproteins
High density lipoprotein is synthesized by the liver and small
intestine and enters the plasma as a discoidal nascent particle.
These particles are composed of a bilayer of phospholipids (mainly
lecithin); the proteins are associated mainly with the disk margin
(Wlodauer et al.., 1979; Hamilton, 1984). The metabolism of nascent
HDL gives rise to the subtractions. In the rat, these are termed
HDL1 and HDL2 (Oschry and Eisenberg, 1982); in man, the
subtractions are HDL^ and HDL 2 (Patsch et al., 1974). HDL2
in rat and human are similar in their physical and chemical
properties. Comparitively, the densities and sizes of the particles
decreases from HDLg-HDL2-HDL^. Chemically, the relative
content of cholesteryl ester and apoE increases from
hdl3-hdl2-hdl1.
On entry into the plasma, cholesterol phospholipid, apoA-I, apoA-IV
and apoC are transferred from the surface of chylomicrons and VLDL
to nascent HDL, producing HDL^ in humans, (HDL2 in rats). The
transfer of these components usually occurs during the hydrolysis of
chylomicrons and VLDL by lipoprotein lipase (Havel, 1978; Patsch e±
al-, 1978). The major apoprotein associated with HDL is apo A-I,
the main activator of LCAT (Fielding and Fielding, 1980). The
surface free cholesterol of HDL2 is esterified via the transfer of
a fatty acid from lecithin by LCAT. The lysolecithin formed is
scavenged by albumin (Stein and Stein, 1966). Cholesterol
esterification is followed by its movement into the core of the
particle. Continuous esterification of the surface free cholsterol
would lead to depletion of surface components, were it not for the
transfer of cholesterol and phospholipid from VLDL and
chylomicrons. Further esterification of the surface free
cholesterol under these conditions leads to the formation of HDL,
(Oschry and Eisenberg, 1982). In humans the process is similar for
the conversion of HDL^ to HDL2.
It is thought that HDL functions to transport cholesterol from
peripheral tissues to the liver and adrenal gland for degradation or
use in other metabolic pathways (Tall and Small, 1980).
14
As mentioned, HDL catabolism results in depletion of surface free
cholesterol and its replenishment by the transfer of surface
components from VLDL and chylomicrons. It can also be replaced by
the transfer of cholesterol from the plasma membranes of peripheral
tissues to HDL (Rothblat and Phillips, 1982; Fielding and Fielding,
1981). In humans and other species, the presence of cholesteryl
ester transfer proteins causes the redistribution of this
accumulated cholesteryl ester from HDL to other lipoproteins of
lower densities. These in turn may be picked up by the liver (Norum
et al_., 1983). Plasma of rats and dogs contains little or no
transfer activity, so that cholesteryl ester produced by the action
of LCAT, and cholesterol picked up from peripheral tissues largely
remains in this lipoprotein class.
1.4.2 Mechanisms of Uptake of Plasma Lipoproteins
(a) Receptor-Mediated Uptake
The most well defined pathway for the uptake of lipoproteins in the
LDL receptor pathway (Goldstein and Brown, 1977). The receptor,
first discovered in cultured human skin fibroblasts, is capable of
binding both apo B and apo E, although its affinity for apo E is
more than 10 times its affinity for apo B (Pitas et al.. 1980).
Studies have shown that small lipoproteins containing several apoE
molecules can bind to several sites (Innerarity al., 1980a),
whereas the apoB on an LDL particle probably interacts with a single
binding site. It is probable that the higher affinity of VLDL
remnants is due to the binding of the remnant to multiple sites on
the receptor through its complement of apoE molecules (Windier et
al., 1980). This higher binding affinity is probably responsible
for the more efficient endocytosis of VLDL remnants than LDL in the
liver.
The accessibility of apo E or apo B, and the size of the particle
appear to influence the uptake of particles. The latter point may
be a function of the greater number of apo E molecules on large VLDL
remnants (Stalenhoef et al., 1984; Packard et al., 1984; Havel,
1984). These VLDL remnants and LDL compete for the apo B/E
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receptor, to which remnant binding is the most efficient. Normal
VLDL, contains apo B and apo E, neither of which effect binding.
The apo E is inaccessible to the receptor (Bradley et al., 1984) and
the apo B differs in its conformation and in its immunoreactivity
from that of the apo B of LDL (Schonfeld et al., 1979). These
factors ensure that it isn't taken up by the apo B/E receptor.
Chylomicron remnants contain apo B-48 not apo B-100, and are not
taken up by the apo B/E receptor. Instead they have a distinct
receptor (Havel, 1984) called the apo E receptor. The existence of
a saturable high affinity pathway for chylomicron remnant uptake was
shown by Sherrill and Dietschy (1978). The proof that this pathway
had a specific receptor was shown in studies on patients with
familial hypercholesterolemia (FH) in which chylomicron remnant
uptake was seen to be unaffected and in Watanabe heritable
hyperlipidaemic (WHHL) rabbits (Brown et al.,1981; Kita et al.,
1982). In both cases the number of apo B/E receptors is either
halved - heterozygous FH - or abolished - homozygous FH. In the
homozygous condition, LDL catabolism occurs via the
receptor-independent pathway whilst chylomicron uptake remains
unaffected, because the expression of the apo E receptor is
unaffected in the above subjects (Goldstein £± al., 1983). Binding
of the chylomicron remnants is impeded by C apoproteins, which
prevents premature uptake of the particles. Loss of these
apoproteins during remnant formation ends triglyceride hydrolysis
and facilitates binding to receptors (Havel, 1984).
The receptor-mediated pathways of LDL, VLDL and chylomicron
catabolism are well understood. In vivo studies show that the liver
is a major site for HDL catabolism (Stein et al-, 1983). In studies
conducted by Sigurdsson et al., (1979) using recirculating perfusion
systems with the liver, it was shown that hepatic degredation of HDL
was only 7% after four hours. Further studies in isolated
hepatocytes demonstrated that the liver plays a major role in HDL
catabolism (Drevon et al., 1977; Ghiselli et al., 1981). Both liver
and steroidogenic cells contain an enzyme resembling hepatic lipase
(Jackson, 1983). HDL binding to this enzyme could lead to
endocytosis selective loss of lipid and then retroendocytosis of a
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lipid depleted particle (Kinnunen et aj_., 1983). Interestingly, in
the rat, HDL cholesteryl esters are taken up primarily by the liver,
adrenal gland and gonads at a much greater rate than apo A-I (Stein
et al., 1983; Glass et &1..1983; van't Hooft el al., 1981). This
mechanism involves binding of the HDL to the cell surface, but
receptor recycling and endocytosis do not appear to be involved
(Pittman et aj_., 1987b).
In cultures of hepatocytes of steroidogenic cells, HDL binds to cell
surfaces by a mechanism different from that of lipoprotein apo
B-100. It is not dependent on calcium ion and is resistant to
proteolysis (Norum et al., 1983; Havel, 1986; Gwynne and Strauss,
1982). This binding might promote influx or efflux of cholesterol
or uptake of cholesteryl esters. In some, but not all cells, LDL
and VLDL compete with HDL for the same site (Bachorik et al., 1982),
and as such are also involved in this selective uptake, but to a
much lesser degree (Pittman et al., 1987a). Further to this, it is
likely the relative apo E content of the HDL particles might
influence their interaction with the B/E or E receptor, and thus
influence any receptor-mediated endocytosis. Certainly, the
predominance of one pathway or route of catabolism has yet to be
defined. HDL comprise a varied and adaptable class of lipoproteins
that are involved in plasma cholesterol transport and are
catabolised, at least in part, by a pathway involving
receptor-mediated endocytosis, as well as other means.
Two other receptors, the B-VLDL receptor and the scavenger receptor,
are involved in the endocytosis of lipoproteins containing apo B,
into cells of reticuloendothelial origin, e.g. macrophages, artery
wall foam cells, endothelial cells (Brown and Goldstein, 1983; Baker
et al_-, 1984). B-VLDL receptors are specific for chylomicrons,
large VLDL of hypertriyglyceridaemic patients and the cholesteryl
ester rich, G-migrating VLDL of cholesterol fed animals (Gianturco
et al., 1982; VanLenten et al., 1983; Goldstein et al.» 1980).
These lipid rich particles are endocytosed, hydrolyzed in lysosomes,
and the lipid re-sterified and stored in the cytoplasm, giving the
cells a foam cell appearance (Brown and Goldstein, 1983).
17
The scavenger receptor is involved in the uptake of chemically
modified proteins; modified to increase their negative charge, as
occurs by acetylation (Brown and Goldstein, 1983). This receptor,
also termed the acetyl-LDL receptor, is not affected by cellular
cholesterol levels, as is the LDL receptor (Mazzone and Chait,
1982). The function of this receptor and the B-VLDL receptor is
probably to clear abnormal lipoproteins and they may also be
involved in the deposition of cholesterol in developing
atherosclerotic plaques.
(b) Non-Receptor-Mediated or Receptor-Independent Uptake
Some LDL in liver and other tissues are endocytosed by pathways not
involving receptor-mediated endocytosis. Fibroblasts from
homozygous FH subjects and hepatocytes from WHHL rabbits are capable
of substantial LDL catabolism although they lack the apo B/E
receptor (Goldstein and Brown, 1974; Attie et al., 1982). This can
be shown in vivo by the high catabolic rates for LDL seen in
receptor-deficient animals (Bilheimer e± al., 1982). Binding
studies have demonstrated the existence of a low-affinity site
through which the pathway is mediated (Kita £± &1., 1981).
Quantitatively, this route have a high capacity for lipoprotein
removal, and Shepherd et al., (1980) has suggested that two-thirds
of LDL catabolism occurs by this route. The exact mechanism of this
pathway is not yet fully understood. Certainly, bulk fluid
endocytosis (pinocytoses), common to all tissues, contributes little
to LDL uptake by FH fibroblasts (Attie et al., 1982), and is no
longer considered. The LDL might absorb to low-affinity binding
sites and be taken up during the course of membrane turnover. This
has yet to be demonstrated conclusively (Attie et al., 1982; Ho et
al., 1977).
1.4.3 Lipoprotein Lipase and Transfer Factors
Lipoprotein lipase (LPL) is the enzyme responsible for the
hydrolysis of the triglycerides and phospholipids of chylomicrons
and VLDL, and is activated by apo C-II (Havel et al., 1970; La Rosa
et al., 1970). LPL is bound to the capillary endothelium and found
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in most extrahepatic tissues. Hepatic lipase, first isolated in the
perfusate of livers treated with heparin, also hydrolyses
triglycerides and phospholipids (Nilsson-Ehle et al_., 1980). It is
immunologically distinct from LPL (Jansen and Hulsmann, 1975) and is
not activated by apo C—II. Lipoprotein lipase is involved in the
metabolism of chlyomicrons and VLDL. Its activity is influenced by
several hormones of which insulin is the most important for
short-term regulation (Jackson, 1983). The function of hepatic
lipase is less clear. It is known that high hepatic lipase levels
decrease plasma HDL-cholesterol whilst low hepatic lipase activity
corresponds to an increase in the rate at which tissues acquire
cholesterol. A role for hepatic lipase in the degradation of IDL as
well as HDL has been speculated (Jackson, 1983; Jansen and Hulsmann,
1985).
Lecithin:cholesterol acyl transferase (LCAT) is another enzyme
involved in plasma lipid metabolism. Its substrates are
phosphatidylcholine and cholesterol, and it produces cholesteryl
esters and lysolecithin. Both hydrolysis and transesterification
are activated by apo A-I, the major protein of HDL (Aron, 1978).
Apo C-I and apo A-IV also activate LCAT. The enzyme acts on fatty
acids on the sn-2 position of phosphatidylcholine. It
preferentially cleaves unsaturated fatty acids and its specificity
for the sn-2 position is partly influenced by the high relative
abundance of sn-l-saturated-sn-2-unsaturated phosphatidylcholines
(Gotto et aT., 1986).
Acyl: coenzyme A: cholesterol o-acyltransferase (ACAT) is an
intracellular enzyme located on the endoplasmic reticulum (Goodman
et al., 1964). Initially, it was found in rat liver (Murkherjee et
al_., 1958), but has since been found in most tissues. It is
responsible for the intracellular formation of cholesteryl esters
from free cholesterol and fatty acids. The activity of the enzyme
may be regulated by an ATP-dependent phosphorylation mechanism
(Suckling et al-, 1983). As mentioned earlier, HMG-CoA reductase is
regulated by such a mechanism and it is postulated that so to is
cholesterol 7a-hydroxylase. Thus, three enzymes of intracellular
cholesterol metabolism may be regulated together.
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Lastly, there is a group of proteins, the 1 ipid-transfer proteins,
that mobilize lipids from one compartment to another. Lipid
transfer among plasma lipoproteins and cell membranes is mediated by
a series of specific protein factors in the plasma. Brewster et
al., (1978) first demonstrated this for the transfer of
phosphatidylcholine. A similar factor is responsible for the
transfer of cholesteryl esters (Zilversmitt ei al.. 1975). Exchange
proteins tend to equilibrate the fatty acid composition of lipids
among the lipoproteins. Net transfer of and not just simple
exchange also occurs, and is an important means of transfer of
lipids from lipoprotein to lipoprotein (Tall, 1986). Phospholipid
exchange proteins are active in all mammalian systems looked at;
however, cholesteryl ester/triglyceride exchange protein activity
varies from species to species. This particular protein has been
intensively investigated, such that its cDNA sequence was recently
eluciated (Drayna, 1987). In the rat however, it is absent and the
type of cholestryl ester transfer it is involved in other species is
not of importance in rat lipoprotein metabolism.
1.5 Summary
In the preceding sections, I have attempted to describe hepatic
cholesterol metabolism, of which the overall picture is complex.
There are a number of sources of cholesterol available to become
intracellular free cholesterol, namely endogenous synthesis, and
uptake of plasma lipoproteins, by eitheoreceptor or non-receptor
mediated pathways. In the rat, the HDL subtraction is of particular
improtance due to its potential role in delivery of cholesterol from
peripheral tissues and because of the absence ofiiDL. Each of these
present a different sound and potentially a different, discrete pool
of free cholesterol.
Once in these potential pools the free cholesterol can then be used
in a number of pathways: secretion into bile or plasma with
lipoproteins, esterification and storage or secretion with
lipoproteins, and finally further metabolism into bile acids and
then subsequent secretion. Again, each of these products might
derive from different precursor pools of free cholesterol. It is
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thus of interest to define the fates of different cholesterol
sources, and the inter-relationship of any potential precursor pools.
Important in the control of these processes and inter-relationships
are three enzymes, all of which are located microsomally and
possibly subject to reciprocal metabolic control: HMG-CoA reductase,
ACAT and cholesterol 7a-hydroxylase. They are key enzymes in the
synthesis, esterification and conversion to bile acids of
cholesterol and its flux. Within the scope of this thesis the
influence of these enzymes on cholesterol metabolism in conjunction
with the effect of different cholesterol sources (newly-synthesised
and HDL-derived) will be investigated. Using specific inhibitors of
the above enzymes, singly and in combination, the effect on bile
acid production and cholesterol and cholesteryl ester secretion was
investigated. This strategy has allowed for the isolation of
particular pathways to see if any relationships of cholesterol flux
occur between said pathways or precursor pools. For instance, by
inhibiting ACAT activity, we can see if either cholesterol secretion
or bile acid synthesis is changed, and if so, to what degree.
Further to this, using a source of newly-synthesised cholesterol
such as mevalonate, its effect in the above situation can be
determined. From this approach we hope to show these different
intracellular pools of cholesterol which though metabolically





Galactose, gentamycin sulphate, insulin, ornithine hydrochloride,
activated charcoal, reduced nicotinamide adenine dinucleotide,
cholesterol, oleic acid, Coomasie brilliant blue G were obtained
from Sigma Chemical Company, Poole, Dorset, U.K.
Sodium pyruvate, cholesterol oxidase, cholesterol esterase,
horseradish peroxidase, bovine serum albumin fraction V pwoder,
bovine serum albimin fraction V powder (fatty acid free) were from
Boehringer Corporation (London) Ltd., Lowes, East Sussex, U.K.
Trypan blue, polyethylene glycol, mercaptoethanol, polyacrylamide
and sodium dodecyl sulphate were from BDH Chemicals Ltd., Poole,
Dorset, U.K.
Non-essential ami no-acids, foetal calf serum, newborn bovine serum
albumin were from Flow Laboratories Ltd, Irvine, Scotland, U.K.
Dubbecco's modified Eagle's medium and streptomycin/penicillin and
nystatin were from GIBCO (Europe) Ltd., Paisley, Scotland, U.K.
Percoll and 4-30% acylamide gradient gels were from Pharmacia (Great
Britain) Ltd., Milton Keynes, Middlesex. U.K.
Cholestyramine was provided by Bristol-Myers Company (U.K.) Ltd.,
Cramlington, Northumberland. U.K.
58-035 was provided by Dr John Heider of Sandoz Research Institute,
East Hanover, New Jersey, U.S.A.
Mevinolin was provided by Mr A. Alberts, Merck-Sharpe and Dohme,
Rahway, New Jersey. U.S.A.
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Bond-eluts were obtained from Jones Chromatography, Hengoed,
Mid-Glamorgan, U.K.
All radiochemicals and radionuclides were obtained from Amersham
International p.I.e., Amersham, Bucks. U.K.
All other chemicals and reagents were of analytical grade.
2.2 Animals
Female Wistar rats (200-250g) were used in all experiments. Animals
were fed either a soft diet, comprising 70% wholemeal flour, 25%
skimmed milk powder and 5% yeast or the soft diet supplemented with
4% cholestyramine (referred to a "diet Z").
2.3 Preparation of Glassware Used in the Isolation of Hepatocvtes
To prevent adhesion of hepatocytes to glassware, any glassware that
was used with hepatocytes was treated as follows. Glassware was
washed with chromic acid (80-85ml saturated sodium chromate in 2.2 1
concentrated sulphuric acid), rinsed in double distilled water, and
allowed to dry. This was followed by treatment with Dri-Film SC87
(10% v/v in petroleum ether). The glassware was then drained,
washed with hot water and dried in an oven at 60°C for 2 hours.
2.4 Preparation and Maintenance of I solated Hepatocvtes
2.4.1 Solutions Required For Isolation of Hepatocvtes
Glucose and Calcium Free Locke's Solution:
Sodium chloride (9 g I-1) and potassium chloride (0.24 g I-1) in
double distilled water.
Glucose and Calcium Free Hank's Solution:
Sodium chloride (8 g l-1), potassium chloride (0.4 g l"1),
magnesium sulphate.7 H20 (0.2 g l-1), potassium dihydrogen
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phosphate (0.06 g T1) and phenol red (0.02% w/v) in 0.01M sodium
phosphate buffer, pH 7.4. Phenol red was used in order to monitor
the pH throughout the perfusion.
2.4.2 Preparation of Isolated Hepatocvtes
The method used for isolation of hepatocytes was upon that developed
by Quistorff et al_. (1973), Botham and Boyd (1979) and Ford (1984).
Rats were anaethetised with diethyl ether. A longitudinal incision
in the abdomen was made and the intestines pushed to one side. The
hepatic portal vein was cannulated and the liver flushed through
with calcium - and glucose-free Locke's solution. Once the liver
had blanched completely the perfusion was stopped, the liver removed
and placed in the perfusion hood (figure 2.1). The liver was then
washed for a further 2 minutes prior to perfusion with glucose - and
calcium-free Hank's solution supplemented with 0.5 mM calcium
chloride and containing 1-1.5 mg ml-1 collagenase for 12-16
minutes. The amount of collagenase used depended upon the
commercial preparation obtained. Finally, the liver was perfused
with glucose - and calcium-free Locke's solution containing 0.2mM
ethyl enediaminetetra-acetic acid (EDTA) for 5 minutes. All
perfusates were oxygenated during perfusion and were supplemented
with 2% (w/v) bovine serum albumin and 38 mM sodium bicarbonate.
The pH of the perfusates was adjusted to pH 7.4 with sodium
bicarbonate if necessary. The procedure was carried out at 30-35°C.
After perfusion, the cells were dispersed in glucose - and
calcium-free Hank's solution by gentle teasing with forceps in a
glass petri dish, and immediately poured through a 200pm nylon mesh
filter into a glass beaker. The isolated hepatocytes were
sedimented by centrifugation and resuspended in 10 ml of culture
medium, consisting of Dulbecco's modified Eagle's medium (DMEM)
supplemented with 0.4 mM ornithine hydrochloride, non-essential
amino acids, gentamycin sulphate (100 mg l-1), penicillin/
streptomycin (10,000 III I-1) nystatin (20 U ml-1) and galactose
(1 g I-1) containing 2% (w/v) charcoal treated bcY/ne serum
albumin. The resuspended hepatocytes were then applied to two 35 ml
Figure 2.1 Liver perfusion apparatus
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'Percoll' density gradients (0-70% (v/v) 'Percoll' in supplemented
DMEM, containing 2% bovine serum albumin). Continuous gradients
were formed using a gradient mixer. Viable cells were separated
from non-viable cells by centrifugation at 50 xg for 15 minutes.
The viable cells formed a pellet or lower band of cells, were
removed and washed with 2 x 15 ml supplemented DMEM with 2% (w/v)
charcoal treated bovine serum albumin. Hepatocytes were finally
resuspended in 10 ml of supplemented DMEM, containing 20% (v/v)
foetal calf serum and insulin (100 U l-1). The complement of
foetal calf serum was inactivated by heating to 56°C for 1 hour.
The viability of this final suspension, determined by trypan blue
exclusion, was routinely greater than 95%.
2.4.3 Maintenance of Isolated Hepatocvtes
The hepatocyte suspension was diluted with supplemented DMEM
containing 20% (v/v) foetal calf serum and insulin (100 If1) to
give a final cell density of approximately 1 x 106 cells ml-1.
The cells were incubated for 3-3.5 hours in 50 mm plastic petri
dishes (2.5-3.0 x 10^ cells 3 ml-1), during which time cell
adhesion occurred. The medium was then removed and replaced with 2
ml of supplemented DMEM or 2 ml of supplemented DMEM with 2% (w/v)
charcoal treated bovine serum albumin, depending on the experimental
conditions required.
2.5 Procedures for the Use of Inhibitory Compounds
2.5.1 Experimental Use of 58-035
58-035, an extremely hydrophobic compound, was dissolved in dimethyl
sulphoxide (DMSO) and stock solutions of 1 mg ml-1 and 10 mg
ml-1 were prepared. Aliquots of between 10-50 pi of these stocks
were used. The hepatocyte monolayer cultures were pre-incubated
with an aliquot of 58-035 and 2 ml of supplemented DMEM with 2%
charcoal treated bovine serum albumin, for 2 hours to facilitate
uptake of the compound. The medium was then changed to that
required by the given experiment, usually 2 ml of supplemented DMEM.
H-NHCO(CH2)2Si(CH3)2C|0H2|
Figure 2.2 Chemical structures of a)58-035 and
b) azacholesterol
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2.5.2 Experimental Use of 6-Azacholes-4-en-3B-o1-7-one
(Azacholesterol)
As with 58-035, azacholesterol was dissolved in DMSO, and stock
solutions of 5 mM, 10 mM ocnd 20 mM were prepared. Aliquots of
between 10-50 pi from these stocks were used. The hepatocyte
monolayer cultures were presented with an aliquot of azacholesterol
and 2 ml of supplemented DMEM with 2% (w/v) charcoal treated bovine
serum albumin. Pre-incubation of the azacholesterol with the
hepatocytes prior to the start of the experiment was not necessary.
2.5.3 Experimental Use of Mevinolin
Mevinolin is transformed from its lactone form by heating at 50°C
for 2 hours in 0.1N sodium hydroxide as shown in reaction (1) (Brown
et aJL, 1978).
8.091 mg of mevinolin was dissolved in 25 ml of 0.1N sodium
hydroxide, and heated. The resultant solution was neutralised with
hydrochloric acid, diluted to 100 ml with 75 ml of 59 mM sodium
bicarbonate, and adjusted to pH 7.4. Thisproduced a stock of 200 pM
mevinolin in 44 mM sodium bicarbonate. Aliquots of between 10-50 pi
of this stock were used. Hepatocytes were presented with an aliquot
of this compound and 2 ml of supplemented DMEM, and pre-incubated
for 1 hours. After this time, the medium was changed to that






2.6 The Viability of Hepatocvtes Maintained as Monolayers
Hepatocyte viability prior to plating was determined by trypan blue
exclusion. After treatment with' DMSO, 58-035, azacholesterol and
mevinolin, viability was assessed by trypan blue exclusion and
leakage of lactate dehydrogenase.
2.6.1 Exclusion of Trypan Blue
Prior to plating, viability was determined by mixing 100 pi of the
hepatocyte suspension, 300 pi culture medium, and 400 pi 0.4% (w/v)
trypan blue solution. An aliquot of the resultant mixuture was
added to a Hawkesly Haemocytometer and the viable and non-viable
cells counted. Monolayer viability was determined by addition of
0.2 ml 0.4% (w/v) trypan blue in 5 ml of culture medium. Monolayers
were incubated for 5 minutes, after which the trypan blue was
removed and percentage viability assessed. In both procedures,
viability was expressed as the percent of cells excluding the dye.
2.6.2 Leakage of Lactate Dehydrogenase
Lactate dehydrogenase was determined spectrophotometrically with
pyruvate and reduced nicotine adenine dinucleotide according to
Vassault (1982). The activity of lactate dehydrogenase was
determined from the rate of oxidation of NADH, by measuring the
decrease in absorbance at 340 nm.
To determine the leakage of lactate dehydrogenase, the enzyme was
assayed in both the culture medium and the disrupted cells. Cells
were disrupted by sonication of approximately 1-1.5 mg ml-1 of
cellular protein in phosphate buffered saline, pH 7.4. An aliquot
was assayed for lactate dehydrogenase activity. The culture medium
was assayed directly. Percentage viability was expressed at
[1—(total units lactate dehyrodgenase in the medium - total units in
the cells)] x 100. The effect on lactate dehydrogenase leakage of
DMSO, 58-035, azacholesterol and mevinolin was assessed after 0 to 5
hours. Addition of the above compounds was a described previously.
After the allotted time period, cells were scraped off the plates
into 1 ml of phosphate buffered saline, pH 7.4, and used as stated
above.
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2.7 Determination of Conjugated Bile Acids
Determination of conjugated cholic, chenodeoxycholic and G-muricholic
acids was by radioimmunoassay (Becket et al_., 1978; Beckett et aj_.,
1979 and Botham e± al., 1983). Bile acid content of the culture
medium was measured directlyj^Si^tk descnUdl tn tire nUiK S
Cellular bile acid content was determined by first extracting the
cells with 1M sodium hydroxide for 24 hours. This procedure has
been demonstrated to extract 1007. of bile acid from tissue samples
(Strange al., 1979)
2.7.1 Preparation of Immunoqens
Immunogens in the following bile salt : bovine serum albumin molar
ratios, cholate (17:1), chenodeoxycholate (18:1) and G-muricholate
(10:1), when prepared by the mixed anhydride method of Erlanger et
al. (1957) as modified by Murphy et al. (1974).
2.7.2 Preparation of Anti-serum
1 mg of each bile acid - bovine serum albumin immunogen in 1 ml of
1:1 (v/v) emulsion of Freund's complete adjuvant in saline was
injected sub-cutaneously into individual New Zealand white rabbits,
a booster injection was given six weeks later using 1 mg of each
conjugate in Freunds incomplete adjuvant emulsion. Blood was
obtained from the ear vein and serum separated from blood by
centrifugation. The anti-serum from these animals was used without
further treatment.
2.7.3 Determination of the Optimum Dilution of The Anti-serum
The dilution of anti-serum used in the assay of each bile acid was
determined by incubation of [^^I]-labelled bile acid histamine
conjugates wiht serial dilutions of the homologous fypfci
i.. • in the presence and absence of the highest
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standard used in each assay. Binding of the [ 13—1abel1ed
ligand to the anti-serum is described in section 2.7.6. The
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anti-serum dilutions that gave the greatest range of binding were
subsequently used in each assay. This produced the most sensitive
assay conditions (Beckett it al_., 1978).
2.7.4 Preparation of Bile Acid-Histamine Conjugates
Bile acid-histamine were prepared by the mixed anhydride method
outlined by Feisen and Feisen (1967). The process is shown in
reation (2).









The following proportions of reactants were used; bile acid, x
moles; triethyl amine, 1.2xmoles; ethyl chloroformate, 1.2 x moles;
histamine, 1.5xmoles. A given bile acid was dissolved in a small
volume (less than 5 mis) of sodium-dried tetrahydrofuran. (THF)
Triethyl amine was added, and the mixture cooled at 4°C.
Ethylchloroformate was added dropwise. The reaction mixture was
stirred for 30 minutes at 4°C, and then histamine (in
tetrahydrofuran) was added. The mixture was stirred at 4°C for 1
hour, and then left stirring at room temperature overnight.
The conjugates produced tended to precipitate out of THF, so all the
products and reaction mixture were dissolved in methanol. The
methanol and residual tetrahydrofuran was then removed by rotary
evaporation.
This left a gummy residue of bile acid-histamine conjugate,
unreacted starting materials and triethylamine hydrochloride. In
the case of the chenodeoxycholate conjugate, the gum was





evaporated off by rotary evaporation. The conjugate precipitated
out of solution, and the water removed by vacuum filtration. Figure
2.3 shows the NMR spectrum of this conjugate.
For the conjugate of cholic and 13-muricholic acid purification was
performed differently because of their greater solubility in water.
The gummy residues were dissolved in methanol and applied to silical
gel columns. The conjugates were eluted off the column using
chloroform : methanol (10:3, v/v). The eluants were rotary
evaporated, leaving behind crystalline residues which were the
conjugates in question.
2.7.5 Iodination of Bile Acid-Histamine Conjugates
Iodination of conjugates was performed by a method based on that
described by Hunter £t al. (1975). 50 nmol of each bile acid
1 OC
histamine conjugate was mixed wiht 1 mCi of sodium [ I]-iodine
and 20 pi of 20 mM chloramine T in 0.5 M phosphate buffer, pH 7.9.
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The [ 13—label 1 ed bile acid histamine conjugate was then
extracted by addition of 0.2 ml of water followed by 0.5 ml of ethyl
acetate. The ethyl acetate layer was collected and the water
removed by drying with anhydrous sodium sulphate. The ethyl acetate
extract was transferred to a silica gel thin layer chromatography
plate and developed in ethyl acetate/toluene/triethyl amine
(50:25:25:10, v/v). This separated unreacted [125I] iodide from
the radiolabeled conjugate. After scanning, the area of the plate
corresponding to the radiolabeled conjugate was extracted with
methanol.
2.7.6 Assay Procedure
Bile salts were determined by using a specific anti-serum with a
homologous bile acid histamine ligand. The assay was performed by
mixing 10 pi of the sample with 200 pi of radio-immunoassay buffer
(100 sodium phosphate buffer, 15 mM sodium azide, 15 mM sodium
chl0ride, pH 7.4) containing newborn bovine serum (10% v/v),
[125j]_iabelled bile acid histamine conjugate and appropriate
antiserum. Anti-serum was diluted to give optimum assay conditions
Figure 2.3
f
Figure 2.3 Structure and NMR Sprectum of Chenodeoxycholate-Histamine
Conjugates. The groups indicated above corresponding to the following
peaks on the spectrum:
a) 3a and 7a-hydroxyl groups at 4.1 and 4.35 ppm.
b) CH3 groups at positions 18 and 19 at 0.6 and 0.8 ppm.
c) CH3 grop at position 21, doublet peak at 0.9 ppm.
d) Amide group at 7.8 ppm.
e) -CH2-CH2-, triplet peaks at 2.6 and 3.2 ppm.
f) Imidazole hydrogens at 6.75 and 7.5 ppm.
No contamination of the above product by unreacted starting materials
or reaction by products is evident in this spectrum.
JU300S.125 RUPROG: XOl.RU DATE30-6-8? SOLVENTDMSO SF250.134 015282.364 RG40 NS24 TE29? LB.300 CX38.10 CT18.50 F110.000P F2-.1OOP PPM/CM.26S SR4037.52
F226S1123/7 5.04 3 PPM
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(section 2.7.3). Samples were incubated at room temperature for at
least 3 hours. The bound ligand was separated from the free by
precipitation with 3 ml 2.57. (w/v) ammonium sulphate, followed by
centrifugation at 3,000 r.p.m. (2560 xg) for 15 minutes at 4°C. The
precipitate was counted using a gamma counter. The bile salt
content was determined from standard curves.
2.8 Separation and Measurement of Cholesterol. Cholestervl Ester
and Bile Salts After Incubation of Hepatocvte Monolayer
Cultures with Radioactive Precursors
Following extraction of samples, cholesterol, cholestryl ester and
bile salts were separated by thin layer chromatography (t.l.c.) or
by elution on silica gel columns.
2.8.1 Extraction of Samples
Lipids and bile acids were exracted from samples after the addition
of sodium hydroxide (final concentration, 1M) using chloroform/
methanol (2:1 v/v) according to the procedure of Folch si &1. (1957).
Cholesterol and cholesteryl ester were partitioned in the
non-aqueous phase. THis was blown down to dryness and the residue
re-dissolved in a known volume of chloroform. The bile salts were
partitioned in the aqueous phase. Sodium hydroxide addition before
extraction improved the recovery of bile salts. The protein
precipitate present in the aqueous phase was removed by a
centrifugation and washed with 2 x 2 ml methanol. The washes were
pooled with the original supernatant, the solvent evaporated and the
residue taken up in known volume of methanol.
2.8.2 Thin Laver Chromatography of Non-aqueous and Aqueous Extracts
The non-aqueous extracts, containing cholesterol and cholesteryl
ester were developed in the following solvent systems:
1. For separation of cholesteryl esters only: petroleum
ether/diethyl ether/acetic acid (glacial) (95:5:0.5, v/v).
Rf value for cholesteryl esters is 0.875.
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2. For separation of cholesteryl esters and cholesterol:
diisopropyl ether/petrole urn ether/acetic acid (glacial)
(70:30:2, v/v). Rf values for cholesteryl esters and
cholesterol are 1.00 and 0.60, respectively.
Samples of the bile salt were developed in ethyl acetate/methanol/
acetic acid/water (35:12:2:2, v/v). Recovery of radioactivity from
the extraction and t.l.c. procedures was followed using known
quantities of appropriate radioactive tracers. Identification of
cholesteryl ester, cholesterol and bile salts was determined either
by scanning the plates on a t.l.c. plate scanner or by running
marker plates with non-radioactive standards. The standards were
visualised by spraying with 1% (v/v) phosphomolybdic acid in
methanol, followed by incubating in an oven for 10 minutes at 70°C.
Bands corresponding to the standards were scraped off the sample
plates into scintillation vials and counted.
2.8.3 Separation of Cholesterol and Cholestervl Ester on Silica Gel
Columns
A new procedure, faster and more convenient than t.l.c. plates, was
developed using silica gel columns (Anachem "bond-elut" columns,
size 3cc, bonded phase SI). The columns were prepared from the
assay by addition of 1 ml hexane/diethyl ether (3:1, v/v). The
residues of dried non-aqueous extracts, containing cholesterol and
cholesteryl esters, were taken up in 0.5 ml of hexane/diethyl ether
(3:1, v/v), and applied to the columns. A further 0.5 ml of
hexane/diethyl ether (3:1, v/v) was used to wash out each sample
tube and then applied to the columns. Once the samples were loaded
onto the columns, a further 1 ml of hexane/diethyl ether (3:1, v/v)
was added to each, and the eluants collected in scintillation
vials. Next, 3 mis of hexane/diethyl ether (1:1, v/v) was added to
each column, and the resulting eluants collected in scintillation
vials. The cholesteryl ester was extracted from the column into the
first eluant collection and the cholesterol into the second eluant
col lection.
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This system brings about the complete separation of cholesterol from
cholesterol ester, but is limited to experimental situations were
there are no significant levels of radioactive label incorporation
either into triglycerides or long'chain free fatty acids.
2.8.4 Assay of Radioactivity in T.L.C. or Silica Gel Chromatography
Samples
Radioactivity present in bands scraped from t.l.c. plates or in the
eluants of silica gel columns wereassayed by addition of 10 ml of
Pico-fluor 15 scintillant, and counted in a Packard scintillation
spectrophotometer.
2.8.5 Determination of Recovery Efficiency
In certain experiments, where the synthesis of products from
radioactive precurssors occurred, prior to extraction and
separation, the exact amount of activity attributable to the
products was unknown. To ensure that the recovery efficiency of
these products could be determined, known quantities of appropriate
radioactive recovery markers were added to samples prior to
14 3
extraction, e.g. for a [ C] cholesterol product, [ H]
cholesterol was the recovery marker.
The percent recovery was determined and used to estimate the
activity of the products prior to extraction.
2.9 Determination of Cholesterol
Free and total cholesterol were determined by the fluorimetric method
of Gamble et al_. (1978).
After extraction of the samples with chloroform/methanol (2:1, v/v),
the non-aqueous infranatant were removed, the solvent evaporated and
the residue taken up in chloroform. Free (unesterified) cholesterol
is oxidised to 4-cholestene-3-one with concomitant formation of
hydrogen peroxide is a measure of the amount of cholesterol present
and is estimated with p-Kydroxyphenylacetic acid. Oxidation of
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p-hydroxyphenylacetic acid yields a fluorescent quinone.
Fluorescent quinone. Fluorescence was detected using a Perkin-Elmer
3000 fluorescence spectrophotometer.
Determination of total cholesterol was carried by first hydrolysing
the cholesteryl esters using cholesterol esterase, and then
estimating the cholesterol present as outlined above.
2.10 Determination of Protein
Protein was determined by the method of Bradford (1976) using bovine
serum albumin as standard.
2.11 Preparation of a Microsomal Fraction from Hepatocvte
Monolayer Cultures for the Determination of Acvl CoA :
Cholesterol Acvltransferase Activity
Having prepared monolayer cultures of hepatocytes, as described in
section 2.4, certain experiments required the preparation of a
microsomal fraction from the cultured cells.
After adhesion of the cells to the plates, the medium was changed to
2 ml supplemented DMEM and the cells incubated overnight. The
medium was then changed to 2 ml supplemented DMEM containing 20%
foetal calf serum (v/v), 58-035 was added in solution in DMSO (20 pi)
to give a final concentration of up to 100 pg/ml of inhibitor.
After a further 2 hours, the medium was removed and the cells washed
and scraped off the plates using 2 x 0.5 ml 0.1 M potassium
phosphate buffer. The resulting suspensions were individually
homogenised, 10 pi removed for protein determination , and the
remainder transferred to Eppendorf tubes and centrifuged at 8,800 x g
in a microfuge for 5 minutes. 100 pi of bovine serum albumin (fatty
acid free) and glutathione solution in potassium phosphate buffer
(each 10 mg/ml) was added to 850 pi of the supernatant. After 30
minutes preincubation at 37°C C^C3 oleoyl CoA (150 pi, final
concentration 42 pM) was added and the mixture incubated for 1
minute. The reaction was stopped by the addition of 2 ml methanol.
Extraction and analysis of products has been described in sections
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2.8.1 and 2.8.2. Acyl CoA : cholesterol acyltransferase activity was
14
taken as a measure of the amount of [ Cloleoyl CoA incorporated
into cholesterol ester mg-1 cellular protein minute-1.
2.12 Non-enzvmatic Hydrolysis of Cholesterol Ester to Determine
Incorporation of a Radioactive Label Into The Fattv Acids of
Cholesterol
In certain experiments synthesis of cholesterol and cholesteryl
esters were measured by observing the incorporation of radioactive
precursssors (acetate, mevalonate) into the molecules in question.
In particular, it was necessary to know the amount, if any, of
radioactive label appearing in the fatty acyl group of cholesteryl
3 14
esters synthesised from [ H] [2- C] mevalonic acid.
250 pi of media, collected from hepatocyte monolayer cultures
3
incubated with C H] mevalonic acid, was added to 1 ml of alcoholic
potassium hydroxide, and heated to 50°C for 1 hour. This was then
followed by extraction with chloroform/methanol (2:1, v/v) (section
2.8.1) and separation on silica gel columns (section 2.8.3). Prior
14
to hydrolysis a known amount of [ C] cholesterol was added to
each sample to act as a recovery marker. After hydrolysis, a known
14
quantity of [ C] cholesteryl oleate was added to each sample to
act as a recovery marker for the esters.
Parallel to this, a further 250 pi of the media samples, with
recovery markers added, were extracted (section 2.10.1) and
cholesterol and cholesteryl esters separated on silica gel columns
(section 2.8.3).
The following equation was determined:-
HFC - FC + xCE
The amount of radioactive label incorporated into the hydrolysed
free cholesterol (HFC) should equal the free cholesterol (FC) plus
the cholesterol ester if none of the label is present in the fatty
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acyl group of the ester. If some label has been incorporated into
the fatty acyl group, then the hydrolysed free cholesterol will be
less than expected i.e. by the factor x.
The hydrolysed free cholesterol (HFC) was determined from the
hydrolysed samples, and the free cholesterol and cholesteryl esters
were determined from non-hydrolysed samples.
2.13 Isolation of Rat Plasma High Density Lipoprotein Subfraction
ihdl2i
Rat HDI_2 was isolated by density gradient ultracentrifugation
(Havel £t al, 1955; Jansen £t al_, 1983). The density range used for
isolation of HDL2 was 1.085 - 1.21 g ml"1. (Oschry and
Eisenberg, 1982).
Blood was obtained from ether anaethetised, female Wistar rats via
the inferior vena cava and cardiac puncture, and collected in 10 ml
polypropylene tubes containing 40 mg EDTA to pfievent clotting. Blood
cells were separated from plasma by centrifugation at 2,000 r.p.m.
(1140 xg) in a Beckman J-6-B centrifuge using a JS-3.0 rotor, at 4°C.
The rat plasma obtained was adjusted to a density of 1.090 g ml"1
by mixing with a high density salt solution (1.346 g ml"1)
containing sodium chloride (158 g l"1), pottasium bromide (354 g
l"1) and EDTA (1 g l"1), pH 7.2. This mixture was added to a
Beckman "Quick-Seal" centrifuge tube and over-layered with a salt
solution of a density of 1.080 g ml"1. This latter solution was
prepared by mixing appropriate volumes of the high density salt
solution with a low density salt solution (1.006 g ml"1)
containing sodium chloride (9 g l"1), EDTA (1 g l"1) and sodium
azide (0.2 g l"1), pH 7.2. The tubes were sealed and then
centrifuged at 49,000 r.p.m. (200,000 xg) in a Beckman L8-70M
ultracentrifuge using a 50.2 Ti rotor for 22 hours at 12°C. After
centrifugation the tubes were sliced open, and the higher density
fraction removed, adjusted to a density of 1.23 g ml"1 as
described previously, added to Beckman "Quick-Seal" tubes, and
over-layered with a salt solution of 1.21 g ml"1.
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The tubes were sealed and centrifuged at 49,000 r.p.m. (200,000 xg),
as described earlier. On completion, the remaining lipoproteins had
floated to the top of the centrifuge tube, and were extracted by
slicing open the centrifuge tube at the appropriate level. The
fraction collected was dialysed overnight against 2 changes of 4
litre water and then reverse phase dialysed using Ccarbo-wax, solid
polyethylene glycol].
2.14 Sodium Dodecvl Sulphate Polvacrvlamide Gel Electrophoresis of
HDU. Apoproteins
SDS-discontinuous Slab-gel electrophoresis was performed according
to the method of Laemmli (1970) with modifications as described by
Douglas and Butow (1976). Gradient gel electrophoresis with a
continuous buffer system was performed according to the method
outlined by Hames and Rickwood (1981).
2.14.1 Solutions Required for SDS-discontinuous Gel Electrophoresis
A) Separating gel buffer : 15 M Tris HC1, 8mM EDTA, 0.4% SDS
(w/v), pH 8.8.
B) Stock acrylamide : 30% (w/v) acrylamide, 0.8% (w/v) N,N'-
methylene bisacrylamide dissolved in water, filtered through
glass wool and stored in the dark at 4°C.
C) Stacking gel buffer : 0.5M Tris HC1, 8mM EDTA, 0.4% (w/v)
SDS, pH 6.8.
D) Polyacrylamide : 1.5% (w/v) polyacrylamide dissolved slowly
in water containing ImM sodium azide and ImM sodium fluoride.
E) Concentrated sample buffer 0.2M Tris HC1 buffer, pH 6.8, 8mM
EDTA 8% (w/v) SDS, 40% (v/v) glycol, 4% (v/v)
2-mercaptoethanol, 0.0025% (w/v) bromophenol blue. Samples
were solubilised in the sample buffer and the diluted 4
times.
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F) Electrode buffer : 50mM Tris-glycine buffer, pH 8.6, 2mM
EDTA, 0.1% (w/v) SDS.
2.14.2 Solutions Required for SDS-Continuous Gel-Electrophoresis
A) Electrophoresis buffer : 40mM Tris HC1, 20mM sodium acetate,
2mM EDTA, 0.2% (w/v) SDS, pH 7.4
B) Concentrated sample buffer : refer to section 2.14.1 E.
2.14.3 Preparation of a Separating Gel
A gel cassette was assembled which comprised two 18 x 18 cm glass
plates separated by two spacers smeared with vacuum grease placed at
both sides of the plates. The cassette was then placed in a 'foil
boat' and the bottom sealed by pouring 12 ml of a solution
comprising 8.75ml solution B, 2.38 ml 2M Tris HC1, pH 8.8, 0.25 ml
10% (w/v) SDS and 1.2 ml water, to which was added 250 pi 10% (w/v)
ammonium persulphate and 10 pi TEMED. TEMED was added to initiate
polymerization. After 30 minutes the gel had set and the foil boat
and excess gel was removed from the bottom of the cassette.
A 15% polyacrylamide gel was then prepared by pouring 30 ml of a
separating gel mixture consisting of 7.5 ml solution A, 15.0 ml
solution B, 5.0 ml D, 2.2 ml water and 0.3 ml 10% (w/v) ammonium
persulphate to which 15 pi of TEMED had been added, into the
cassette. Secondary butanol, saturated with water was carefully
layered onto the separating gel, which was then left to set. After
1 hour, the secondary butanol was removed and a stacking gel
prepared. The stacking gel mixture consisted of 1.2 ml solution B,
2.0 ml solution C, 1.3 ml solution D, 3.4 ml water, 15 pi TEMED. A
toothed comb was inserted into the top of the cassette, and the
stacking gel allowed to set. Whem polymerisation was complete the
toothed comb was carefully removed and samples placed into sample
holders.




The Viability of Rat Hepatocvte Monolayers
3.1 Introduction
The work initially performed by Berry and Friend (1969) on the
isolation of hepatocytes and that by Bissell et al_., (1973) on
culturing hepatocytes in non-proliferating monolayers were the first
to demonstrate the feasibility of this approach in the study of
functional aspects of the liver. Investigations over short time
periods of a few hours use parenchymal cells in suspension, whilst
longer term studies use monolayer cultures. Both of these
techniques have been useful in studying certain aspects of
cholesterol and bile acid metabolism.
The obvious advantages of these procedures are that a number of
experiments can be performed on cells from the same animal, whilst
use of a defined culture medium allows control of the extracellular
enviroment. Particularly, investigations involving the catabolism
of different lipoprotein classes are not hindered by the problem of
in vivo exchange of the lipid and protein moieties between said
classes. As with all models of biological systems there are
disadvantages in using these techniques .
Firstly, there is the physical consideration that the cells are not
in their normal orientations. In vivo, hepatocytes are in contact
with three compartments
i) the perisinusoidal or space of Disse.
ii) the intercellular space,
iii) the bile canaliculi.
Studies on isolated plasma membrane fractions (Wisher and Evans,
1975) have demonstrated functional differentiation of the hepatocyte
plasma membrane. Bile acids are taken up on the sinusoidal surface
and secreted on the canalicular side. This distinct membrane
polarity is lost once the hepatocytes have been isolated, which
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might cause certain problems. For example, the hepatocytes will
synthesize and secrete bile acids and lipoproteins into the culture
medium from where they can be taken up (Iga and Klaassen, 1982)
which in turn might effect the control mechanisms under study.
Furthermore, it is not possible to determine into which compartment,
bile or plasma, various secretions are made.
Some circulating hormones normally present in the plasma are known
to influence the metabolism of cholesterol. These normal metabolic
interactions are not catered for using defined culture medium.
Also, whilst this procedure allows for the investigation of the
catabolism of defined lipoprotein classes, it is likely that
transfer and exchange of components between said classes provide a
mechanism by which lipids are removed from plasma. Thus, it is
essential to consider these problems when trying to use isolated
hepatocytes to answer specific metabolic questions.
Along with the theoretical considerations there are also practical
problems in using rat hepatocytes. Work done previously (Ford,
1984; Ford et al., 1985a) outlined and defined many of these
details. Isolation of the hepatocytes really starts with the
digestion of the intercellular matrix by collagenase, first
described by Berry and Friend}(1969), and later modified by a range
of investigators (Quirstorff et al., 1973; Seglen, 1973). Most
modifications are concerned with the preparation of crude
collagenase used in the isolation procedure. The varying digestive
powers of the collagenase obtained by these methods will have a
marked effect on the initial viability of the hepatocytes. From my
experience, a good commercial preparation or batch of collagenase
should be obtained. Certainly the efficiency of digestion should be
such that no more than 1.5 mg collagenase per ml of perfusate should
be necessary, nor should the perfusion time exceed 16 minutes.
Maintenance of the hepatocytes once isolated presents the next
series of problems. The culture media used in many experiments
required supplementation with foetal calf serum (heat-inactivated)
and insulin to ensure adhesion of the hepatocytes to the culture
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surface. After over- or under- digestion of the liver, resulting in
total non-viability, lack of adhesion of the hepatocytes, was the
cause of experimental failure, usually due to the inactivity of the
insulin used.
Ford (1984) in his work on characterisation of rat hepatocyte
monolayers investigated a number of methods for assessing hepatocyte
viability. The methods chosen by Ford; trypan blue exclusion, LDH
leakage, protein synthesis and measurement of cellular content of
cytochrome P-450, are only a few of the criteria available (Crisp
and Pogson, 1972; Baur et aj_.; 1975). It is clear from his work
that the plasma membranes of hepatocytes remain intact and the
hepatocytes maintain protein synthesis over 24hours. Thus for the
system of rat hepatocyte monolayer cultures used in the following
work, trypan blue exclusion was used as the criteria for assessing
viability in all experiments. Preliminary viability experiments
with the compounds used with the heptocytes were conducted using
both trypan blue exclusion and LDH leakage.
3.2 Exclusion of Trypan Blue bv Rat Hepatocvte Monolayers
Viability was determined at 0 and 5 hours under the variety of
conditions required for later experiments (refer to Chaper 2.5.1 -
2.6.1). Thus the effects of mevinolin, 58-035, 58-035 + mevinolin,
DMSO, and azacholesterol on the ability of hepatocyte monolayers to
exclude trypan blue was assessed.
From Table 3.1, the results show that over the time period of 5
hours, viability of cells adhered to the plates remained greater
than 90% and none of the culture conditions differed significantly
from the control values. During the period of incubation an
apparent loss of cells occurred on some plates usually of the order
of 6.0 x 104 cells, less than 3% of cells originally plated out.
This loss was neither significant nor apparently related to the
particular experimental conditions.
Experiment
1 Viability Total LDH Activity % LEH Activity
6.Time Trypan Blue (U per 2.5x10

























































f) Azacholesterol 0 97.5 2.82 69.1 30.1
Table 3.1
Assessment of the viability of hepatocyte monolayers by trypan blue
exlusion (expressed as a percentage) and LDH leakage after 0 and 5 hours as
affected by treatment with : a) Control, 2 mis DMEM with 21 bovine serum
albumin (fatty acid free); b) Control + 20 pi DMSO; c) Control + 200 pg
58-035 in 20 pi DMSO; d) Control + mevinolin (5 pM); e) Control + 58035
(200 pg) + mevinolin (5 pM); f) Control + Azacholesterol (500 pM).
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3.3 Leakage of Lactate Dehydrogenase bv Rat Hepatocvte Monolayers
The results as determined by the measurement of LDH in the cellular
and media compartments (Table 3.1) indicate that 30% of cellular LDH
leaks into the media over 5 hours for both the control and the
experimental conditions. This leakage of LDH was to be expected
when compared to previous investigations (Ford, 1984).
Interestingly no difference occurs between control and experimental
samples, indicating that the compounds used have not affected the
cells viability.
3.4 Piscussion
The various experimental conditions to which the hepatocyte
monolayers were subjected did not affect their viabilities. There
was no difference between the results obtained for the control and
experimental samples as measured by either trypan blue exclusion or
LDH leakage. Although, leakage of LDH did occur for both
experimentals and controls, this was within expected values and not
due to any experimental treatment.
Thus, for later experiments trypan blue exclusion alone was used for
assessment of cells used for culture, and was considered a
sufficient guide to their viability.
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CHAPTER 4
The Effect of Compound 58-035 on Cholesterol Metabolism and Bile Acid
Svnthesis
4.1 Introduction
In Chapter 1, cholesterol metabolism was discussed fully and the
fates of hepatic cholesterol described. As follows, free
cholesterol can be secreted either into the plasma associated with
lipoproteins, or into the bile canaliculi. It can be further
metabolised into bile acids and secreted into bile; and can be
esterified and stored or secreted into the plasma with
lipoproteins. The existence of these different metabolic roles for
cholesterol raises the possibility that different intracellular
pools of free cholesterol are responsible for the various discrete
products (Stone et aJ_., 1985; Stone £t al_., 1987; Botham, 1986;
Ford ei al_., 1985a).
Esterification of cholesterol occurs by the action of the microsomal
enzyme Acyl-CoA: cholesterol acyl transferase. (Suckling and
Stange, 1985). It is thought that any modifications of the activity
of this enzyme may have important consequences for the fate of free
cholesterol. Certainly, if the activity of ACAT is inhibited, the
possibility exists that the free cholesterol normally utilized would
be used elsewhere. It is thus important to determine the fate of
cholesterol under these conditions, as it would elucidate the
interconnection of different pathways of cholesterol metabolism.
The Sandoz compound 58-035 has been shown to be a potent inhibitor
of this enzyme, and is thus of use in studying intracellular
cholesterol metabolism. It has been shown to inhibit ACAT activity
in hepatoma cells, gut cells, ovarian cells, macrophages, bovine
adrenal cortical cells and fibroblasts (Ross et al_., 1984, Ross &
Rowes, 1984; Veldhuis et aj_., 1985; Oamal et a]_., 1985; Havekes,
1987; Middleton, 1987).
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The effect that the inhibition of ACAT has on intracellular
cholesterol metabolism varies depending upon the cell type. In
macrophages, 58-035 enhanced the down-regulation of LDL receptors
and HMG-CoA reductase by LDL, and decreased cellular accumulation of
cholesterol derived from LDL (Tabas £t al., 1986); whereas in
fibroblasts, 58-035 inhibited ACAT without affecting receptor
numbers (Middleton, 1987). In macrophages ACAT competes for a
regulatory pool of cholesterol that mediates LDL receptor
down-regulation, which isn't the case in fibroblasts. Middleton
(1987) suggests that fibroblasts have two interconnected but
distinct pools of cholesterol, one involved in LDL-receptor
down-regulation; the other providing substrate for ACAT.
Inhibition of ACAT in two types of steroidogenic tissues, ovarian
and adrenal cortical cells, resulted in increased progesterone and
Cortisol secretion respectively, indicating a/\correlation between
the pool or pools of cholesterol for esterification and
steroidogenesis (Oamal £t aJL. , 1985; Veldhuis et al., 1985). The
situation is not as uniform as it might seem from the above, for
cellular responses to trophic hormones and other factors differ in
these cells. In the ovarian cells, 58-035 enhances the effect of
trophic hormones but in combination with LDL does not increase
steroidogenesis above that seen with 58-035 alone. In the adrenal
cortical cells, 58-035 did not augment the effect of a trophic
hormone.
These examples demonstrate that although the basic action of 58-035,
inhibition of ACAT, occurs in all tissues investigated, the overall
effect on intracellular cholesterol metabolism varies. This
variation will depend largely upon the basic functions of different
cell types. These functional differences may in turn be seen in
differences in the intracellular architecture and organisation,
resulting in the existence of different cholesterol pools with
distinct functions depending upon the cell type.
The following experiments were performed to characterise the effects
of 58-035 in rat hepatocytes in monolayer culture.
: 44 :
Initial in vitro work on rat liver microsomes showed that 58-035
inhibited ACAT activity to 12% of controls. Stimulation of ACAT
activity
ty a number of means, by 25-hydroxycholesterol, by an ATP dependent
process and by addition of cholesterol in a number of ways, was
carried out. In each case 58-035 inhibited the activated system to
levels similar to those of control assays containing 58-035 and
microsomes alone. 58-035 is therefore able to inhibit ACAT activity
whatever the state of the enzyme in vitro. It did not inhibit rat
liver microsomal 7a-hydroxylase at the concentrations required to
inhibit esterification, or at concentrations 40-times that (Sampson
£t ilL. , 1987a). With this information in mind, it was decided to
determine the effect of 58-035 on the fate of newly synthesized
cholesterol within the hepatocytes from mevalonate. This approach
has been used to study cholesterol esterification and VLDL secretion
and assembly in monolayer cultures of rat hepatocytes, Drevon et
aj_., 1980a; Drevon £t al., 1980b; Davis et al., 1982); and to
study the dependence of bile acid synthesis on substrate supply in
the same system (Davis et 4l., 1983a; Davis et al.. 1983b). In
work already mentioned, mevalonate provides a substrate for
cholesterol synthesis that by-passes the enzyme HMG-CoA reductase,
ensuring synthesis of free cholesterol without the effects of normal
metabolic regulation. Although not as close to a physiological
model as work with lipoproteins, this approach allows the definition
of intracellular cholesterol metabolism under mechanisms of
substrate supply which are both understood and defined (Drevon et
al., 1980a). This will thus provide the background for
investigations involving lipoproteins described in Chapter 6.
4.2 Effect of 58-035 on Cholesterol Esterification in Rat
Hepatocvte Monolayers
These initial experiments were to determine whether 58-035 could
enter the intact cells and inhibit cholesterol esterification. Rat
hepatocyte monolayers were prepared as described in Chapter 2.
58-035 was presented to the cells as a solution in DMS0 (0-200
pg/dish in 20 pi) in the presence of bovine serum albumin (2-5%
Figure 4.1
Inhibition of cholesterol esteriflcation in monolayers of rat
hepaotcytes by 58-035. 58-035 was added 1n amounts ranging from 0
to 200pg in 20pl DMSO, as stated in Chapter 2.5.1. After the 2 hour
pre-incubation microsomal supernatants were prepared from the
cultures as described in Chapter 2.11, and ACAT activity measured.
The results are in units of pmole min-1 mg-1 cellular protein, ±




(w/v)). Following a 2 hour incubation with the inhibitor, the
formation of cholesteryl C^C] oleate from [^C] oleoyl-CoA in
the 8800 x g supernatant prepared from the cells (Chapter 2.11).
Fig 4.1 shows that inhibition of esterification occurs under the
condition used, reaching a maximum of approximately 80% at doses of
100 pg/dish or greater. Experiments carried out in which bovine
serum albumin was absent from the culture medium failed to produce
inhibition of esterification any greater than 30% at doses of up to
300 pg/dish, indicating that for efficient delivery of 58-035 to its
target enzyme, protein in the culture medium is essential.
In these experiments and those following, controls with and without
DMSO were used, showing no effect of DMSO on cholesteryl ester
formation and secretion or bile acid synthesis and secretion. Also
after the 2 hour incubation with 200 pg per dish of 58-035 in the
presence of 2% BSA, the medium was changed, fresh medium without
inhibitor added and the cells incubated for up to 23 hours, followed
by preparation of the 8800 x g supernatant and assay of ACAT
activity. Under these conditions, inhibition was still observable,
remaining at approximately 80%. This indicates that 58-035 remains
associated with the cells even after the donor medium is removed,
given a sufficient (2 hours) incubation time.
To confirm that inhibition of esterification occurs in intact cells,
3
the incorporation of potassium [ H] oleate into cholesteryl oleate
was measured. Following incubation for 2 hours with 58-035 (100 or
200 pg/dish) in the presence of 2% (w/v) bovine serum albumin, the
3
medium was changed, potassium [ H] oleate (1 mM) and
25-hydroxycholesterol (20 pg/dish in 10 pi of ethanol) in the
presence of 5% (w/v) bovine serum albumin was added, and the cells
incubated for 1.5 hours.
Table 4.1 Shows that 58-035 effectively inhibits cholesterol
esterification in intact cells. It also shows that addition of
25-hydroxycholesterol stimulates cholesteryl ester formation (Drevon
et al.. 1980a). This stimulation was inhibited by 58-035, but in
each case 25-hydroxycholesterol increased the extent ester formation
by about 2.8 fold.
Experiment
Cholesterol Esterification
p mole per hour per dish 1 of control
a) Control 205 ±8 100
b) DMSO 198 ± 6 96.6
C) 25-OH 555 ± 43 271
d) 25-OH 541 ± 25 264
+ DMSO
e) lOOpg 35 ± 4 17.1
58-035
f) 200(jg 34 ± 1 16.6
58-035






100 ± 11 48.8
Table 4.1
The effects of 58-035 and 25-hydroxycholesterol on cholesterol
esterification in rat hepatocyte monolayers. Cholesterol
esterification in intact cells was measured by following the
3
incorporation of potassium [ H] oleate into cholesteryl ester
under the following conditions: a) control, b) 20pl DMSO added to
the medium, c) 25-hydroxycholesterol (lOpg ml-1), d) 25-hydroxy
cholesterol + DMSO, e) lOOpg 58-035 in 20pl DMSO, f) 200pg 58-035 in
20pl DMSO, g) lOOpg 58-035 + 25-hydroxycholesterol and h) 200pg
58-035 + hydroxy cholesterol. The table shows the mean ± S.D. (n=4).
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4.3 Effect of 58-035 on the Secretion of Bile Acids bv Rat
Hepatocvte Monolayers
Previous work has shown that monolayers of rat hepatocytes secrete
cholate, chenodeoxycholate and B-muricholate over periods up to 18
hours in culture and that these represent more than 90% of bile
acids synthesized by rat hepatocytes. The greatest rate of
synthesis occurs over the first 5 hours of incubation. The amount
of bile acids secreted by a preparation of hepatocytes can be varied
by altering the diet of the rats concerned (Ford et al., 1985a).
The diets used then comprised a soft diet (fibre free), pellet diet,
and soft diet supplemented with 4% cholestyramine, (a
bile-acid-binding resin). Synthesis and secretion of bile acids was
highest in hepatocytes derived from rats fed the diet containing
cholestyramine and lowest in cells from the rats fed the soft diet.
In the following experiments, rats fed on both the soft diet and the
cholestyramine-supplemented diet Z were used.
Evidence suggests that the rate of bile-acid synthesis, regulated by
the activity of cholesterol 7a-hydroxylase (Chapter 1.3), is
dependent upon the supply of substrate cholesterol (Ford £i &]_.,
1985b, Davis et &L., 1983 a and b). To investigate the role played
by ACAT in the rat hepatocytes, monolayers were incubated with and
without 58-035 in the presence of increasing concentrations of
mevalonic acid (0-10 mM), used to provide a substantial source of
intracellular cholesterol. Secretion of the 3 bile acids into the
cultured medium was measured after 5 hours by radioimmunoassay.
Nine animals, 4 fed the soft and 5 fed diet Z, with basal rates of
bile acid secretion ranging from 0.2 nmol/mg cell protein to 4 nmol
in 5 hours, were studied. The results obtained were treated in 2
ways due to the wide variation in the basal rates. Firstly, the
amounts of the bile acids secreted in 5 hour were expressed as the
increase in bile acid secretion over that obtained with the control
incubations in which no 58-035 or mevalonic acid had been added.
The mean of these values was calculated and statistical significance
between the incubations with 58-035 present and absent was evaluated
using the Students t-test. These results are shown in Tables 4.2
and 4.3. Alternatively, the data from paired incubations with and
Diet and
animal number Experiment Q
[Mevalonic Ac1d](mM)
1 5^ 10**
All animals Control 1 ± 0 1.175 1.066 1.182
(9) ± 0.057 ± 0.074 ± 0.079
Inhibitor 1.066 1.246 1.342 1.474
± 0.06 ± 0.099 ± 0.064 ± 0.148
Soft diet Control 1±0 1.131 1.047 1.174
(4) ± 0.099 ± 0.133 ± 0.105
Inhibitor 1.051 1.165 1.261 1.334
± 0.03 ± 0.091 ± 0.085 ± 0.120
Diet Z Control 1±0 1.210 1.081 1.189
(5) ± 0.072 ± 0.108 ± 0.125
Inhibitor 1.077 1.310 1.407 1.586
± 0.112 ± 0.158 ± 0.089 ± 0.251
Table 4.2
The effect of 58-035 on bile acid secretion in the presence of
mevalonic acid in hepatocyte monolayers. 200pg of 58-035 per dish
of 2.5 x 106 cells was added and incubated for 5 hours, and the
bile acids measured by radioimmunoassay. Raw data showed a
significant difference between control and inhibitor experiments at
*5mM mevalonic acid (p=0.195%, one-tailed) and **10mM mevalonic acid
(p=0.39%, one-tailed), when analysed by the Wilcoxon signed rank
test. Students t-tests of the paired normalised data data above
also showed significant differences at 5 and lOmM mevalonic acid
(p<0.05). The table shows the mean ± S.E. of the normalised values.
Figure 4.2
The effect of 58-035 on bile acid secretion in the presence of
mevalonic acid in hepatocyte monolayers. For details refer to the
legend on Table 4.2 (□) control experiments; (■) experiments in
the presence of 200pg per dish of 58-035.
Figure 4.2
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without 58035 were compared directly by the Wilcoxon signed rank
test. These results are included in the legends of Tables 4.2 and
4.3
As data had been collected from animals on 2 different diets, and on
3 individual bile acids, a number of comparisons were possible.
Firstly, the effects of 58-035 and mevalonate on total bile acid
secretion in all animals combined was looked at, and then the
effects of the different diets were looked at to see if any
difference due to the activity of cholesterol 7a-hydroxylase could
be discerned. Secondly, the secretion of the 3 bile acids were
looked at to see if one or other was more effected by the
experimental conditions. Cholate was looked at individually,
whereas chenodeoxycholate and B-muricholate were combined because
they are both synthesized on the same branch of the bile acid
pathway (Chapter 1.3 and Figure 1.2).
Whichever method of analysing the results was chosen, when looking
at the combined data from all animals, 58-035 was found to cause a
highly significant increase in the secretion of bile acids from the
cells at concentrations of mevalonic acid over 5 mM (1.26-times
control at 5 mM and 1.25 - times at 10 mM). No significant increase
was seen in absence of mevalonic acid. (Table 4.2 and Figure 4.2).
When examining total bile acid secretion with respect to the diet of
the animals, the Wilcoxon signed rank test was not applicable, as
the sample size was not large enough, so only the Student's t-test
comparison was undertaken. The results (Table 4.2) show that the
increase in bile acid secretion due to 58-035 is most marked in
cells from animals on diet Z, where the basal rate of bile acid
secretions was high.
Looking at the data for cholate and Cchenodeoxycholate +
G-muricholate] as outlined in Tables 4.3 and 4.4, one can see the
same trends as shown by total bile acid secretion (Table 4.2) are
apparent in both. This indicates that 58-035 is having the same
effect, increasing bile acid production in the presence of 5mM and
lOmM mevalonic acid, but not in its absence, on both branches of the
bile acid production. There is little difference between cholate or
Table 4.3
The effect of 58-035 on the secretion of the bile acids (refer to
the legend of Table 4.2). a) cholic acid and b) [chenodeoxycholate
+ 6-muricholate]. Significance as tested by the Wilcoxon signed
rank test showed differences between control and inhibitor
experiments raw data at *5 and**10mM mevalonic acid for a) cholate
at p » 0.195% and p» 4.89% respectively; b) [chenodeoxycholate +
8-muricholate] at p - 0.195% and p = 0.390%.
Diet and
Animal # Experiment Q
[Mevalonic acid](mM)
1 51 ■ 2SH1
a)
All animals Control 1 ± 0 1.079 0.990 1.163
(9) ± 0.069 ± 0.980 ± 0.091
Inhibitor 0.999 1.125 1.214 1.374
± 0.052 ± 0.105 ± 0.065 ± 0.143
Soft diet Control 1 ± 0 1.038 0.971 1.091
(4) ± 0.151 ± 0.160 ± 0.114
Inhibitor 0.986 1.066 1.176 1.300
± 0.085 ± 0.143 ± 0.119 ± 0.118
Diet Z Control 1±0 1.111 1.006 1.220
(5) ± 0.054 ± 0.086 ± 0.142
Inhibitor 1.008 1.173 1.265 1.434
± 0.072 ± 0.162 ± 0.091 ± 0.192
b)
All animals Control 1.0 ± 0 1.213 1.065 1.192
(9) ± 0.051 ± 0.064 ± 0.086
Inhibitor 1.083 1.291 1.383 1.491
± 0.081 ± 0.076 ± 0.048 ± 0.107
Soft diet Control 1.0 ±0 1.203 1.104 1.257
(4) ± 0.097 ± 0.142 ± 0.119
Inhibitor 1.101 1.244 1.338 1.394
± 0.063 ± 0.088 ± 0.079 ± 0.159
Diet Z Control 1.0 ±0 1.221 1.033 1.140
(5) ± 0.062 ± 0.046 ± 0.129
Inhibitor 1.069 1.329 1.420 1.568
± 0.145 ± 0.124 ± 0.063 ± 0.152
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[chenodeoxycholate + 8-muricholate] in terms of the relative
increases in secretion, and increased secretion of one bile acid
alone cannot account for the increase in total bile acid secretion.
In a later experiment, there were no differential effects observed
between cholate or [chenodeoxycholate + B-muricholate] production by
any of the conditions used, so only effects on total bile acid
production will be discussed. Certainly, under the conditions
looked at, the effects are evenly distributed over all bile acid
secretion.
4.4 Effect of 58-035 on the Secretion of Cholestervl Esters bv
Rat Hepatocvte Monolayers
In conjunction with the work conducted on the secretion of bile
acids just outlined, the secretion of cholesteryl ester into the
medium was also examined. Firstly, the nature of the lipoprotein
particles in which the cholesteryl ester was secreted was
determined. It was believed that ester would be secreted with
VLDL-like particles of d<l .03 (Davis etal., 1979; Davis, et al.,
1980; Davis £t al., 1982; Drevon al; 1980a). This fraction was
prepared by ultracentrifugation of media from incubations of rat
hepatocyte monolayers for over 5 hours.
The fraction of density less than 1.03 was analysed for lipid
composition and apolipoprotein content by SDS-polyacrylamide gel
electrophoresis. The lipid composition was triacylglycerol:
phospholipid: free cholesterol: cholesteryl ester; 100: 20: 10:
14: and apoproteins, apoB, apoC and apoE were detected on the gels.
The amount of cholesteryl ester in this fraction was 90% of the
total cholesteryl ester in the medium.
The presence of mevalonic acid resulted in an increase in
cholesterol ester secretion, as expected (Drevon et al., 1980 a and
b). The secreted ester was now to be found in lipoprotein density
fractions other than del.03. 27% was present in the d< 1.03
fraction, 22% was present in the fraction of range 1.03 - 1.08 and
the final 27% was located in the fractions of range 1.08 - 1.23.
Figure 4.3
Effect of 58-035 on cholesteryl ester secretion 1n the presence of
mevalonic acid 1n hepatocyte monolayer cultures. The points show
the cholesteryl ester secreted relative to the control and are the
mean ± S.E. of eight independent experiments. Comparison of paired
data for each animal by the Wilcoxon signed rank test showed a
significant decrease 1n cholesteryl ester over controls at OmM
(p=0.78%), ImM (p-3.9X) and 5mM (p«3.1%). *Means are significantly
different (p<5%) from control (calculated by Student's t-test on the
normalised data. (□) control; (■) + 200pg of 58-035.
Figure 4.3
49
Thus, all the cholesteryl ester secreted was accounted for in one of
the lipoprotein fractions. Considering that the densities quoted,
d<1.03, 1.03 - 1.08, and 1.08 - 1.23, correspond to the lipoproteins
fractions VLDL, LDL, and HDL, it appears that the increase in
cholesteryl ester secretion is being distributed amongst a wider
range of lipoproteins and that, in the case of HDL, an increase in
the secretion of other lipoproteins is also occurring. It may well
be that the increased levels of secreted cholesteryl ester, once
exchange between the lipoprotein moieties has equilibrated, are
responsible for this difference of proportional distribution. This
is unlikely, however, as the results in the absence of mevalonate
would not show such of distribution of cholesteryl ester. More than
likely, during the incubation period, some of the particles of
d<l.03 are metabolised by interaction with the hepatocytes and by
some exchange of lipids/cholesteryl ester with other secreted
lipoproteins to form the group of particles making up the density
range 1.03 - 1.08. Along with this there will be probably an
increase in the secretion of nascent HDL particles which will
interact with the secreted VLDL and exchange protein/lipid factors,
contributing to the range 1.03 - 1.08 and making up the range 1.08 -
1.23.
As observed with the bile acid secretion data, the rates of
secretion of cholesteryl ester by the cells varied widely, from 0.36
to 10.4 nmol/mg cell protein in 5 hours. The amounts of cholesteryl
ester secreted by the cells in the presence and absence of 58-035,
and of increasing concentrations of mevalonic acid (0-10 mM) were
compared as outlined for the bile acids in Chapter 4.3. Cholesteryl
ester secretion was increased 1.5 times by the addition of mevalonic
acid. The presence of 58-035 inhibited ester secretion at
concentrations of mevalonic acid from 0 to 5 mM (42% of control at
zero; 37% at 5 mM). The effect of 10 mM mevalonic acid, in the
presence and absence of 58-035 was not significant. Since
inhibition of ACAT is approximately 80% complete in these
experiments, it is probable that any effect of 58-035 at lOmM
mevalonic acid was probably negated by the large excess of free
cholesterol present in the cells.
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No effect of 58-035 was seen on the secretion of free cholesterol,
the free cholesterol secreted in the presence of 58-035 in all
experiments was 1.14 ± 0.35 (SD., n = 21) of the corresponding
incubations without 58-035. The free cholesterol secreted by the
hepatocytes could be for secretion either into bile of plasma
compartments. Unfortunately, due to this ambiguity inherent in both
the monolayer and suspension techniques, no conclusions with regards
to the fate of the secreted free cholesterol can be drawn from the
data obtained.
4.5 Piscussion
The preceding experiments have shown that 58-035 is an effective
inhibitor of ACAT in both microsomal preparations from rat
hepatocytes and the intact cell, inhibiting ACAT activity by
approximately 80%. The use of this compound has allowed a
comparison of the availability of newly synthesized free cholesterol
in the hepatocyte for esterification and secretion of lipoproteins
with its use for the synthesis of bile acids. Under the
experimental conditions used, bile acid secretion was increased in
the presence of 58-035, but only when an excess of free cholesterol
was available. Conversely, ester secretion was decreased as
expected, but at a high concentration of mevalonate this effect was
not significant; free cholesterol secretion was unaffected by
58-035.
Thus, in the presence of 58-035 ester secretion drops and
accumulation of intracellular free cholesterol occurs due to
mevalonate, before the increase in bile acid secretion becomes
significant. It can be seen that the substrate pools of cholesterol
for bile-acid synthesis and for esterification can interact.
Although the changes in bile-acid synthesis and esterification are
in opposite directions, there is not a molar correlation of the two
trends. This may be because neither substrate pool are saturated
(Botham, 1986; Suckling, and Stange, 1985), which would appear to be
the case under the conditions in these experiments, as the addition
of mevalonic acid alone inceased secretion of both products. The
trends observed are confirmed by other studies in rat hepatocytes
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that show that bile acid synthesis is positively correlated with the
amount of free cholesterol in the cell, but negatively correlated to
with the amount of cholesteryl ester present (Botham and Boyd, 1987).
Thus, the data obtained demonstrates the possibilities for the
movement of newly-synthesized free cholesterol within the hepatocyte
from one pathway to another. Later experiments will investigate




The Effects of 6-Azacholes-4-en-3B-o1-7-one on Cholesterol Metabolism
and Bile Acid Synthesis
5.1 Introduction
In Chapter 1.3, bile acid synthesis and its regulations was
discussed. As mentioned, 7a-hydroxylation is the first and rate
controlling step in the synthesis of bile acids using the enzyme:
cholesterol 7a-hydroxylase. This enzyme is located in the
endoplasmic reticulum of hepatocytes, requires oxygen, NADPH and a
thermostable co-factor and is dependent upon a minor species of
cytochrome P-450. The activity of this enzyme is influenced by a
number of factors. Feed back inhibition occurs in vivo, but not in
in vitro culture systems, (Davis et al, 1983a), suggesting that a
metabolite of bile acids produced in the intestinal lumen is
responsible for this control. There is also the possibility of a
phosphorylation-dephosphorylation (active-inactive) mechanism in
operation, but this is disputed (Kwok &1-, 1983; Berglund si &1-,
1986).
In the following work, the same approach as used in Chapter 4 was
applied to cholesterol 7a-hydroxylase. By blocking the activity of
a key enzyme such as cholesterol 7a-hydroxylase, it might be
possible to determine the fate of the accumulated excess free
cholesterol, and as such, elucidate any interconnections between the
substrate pool or pools of free cholesterol used in bile acid
synthesis or alternative pathways.
In vivo work using a similar approach, examined the role of ACAT in
hepatic cholesterol esterification and its relationship with the
secretion of cholesterol into bile. (Nervi et al., 1984) and found
that a reciprocal relationship exists between ACAT activity and
biliary free cholesterol output. The work by Stone et al. (1987)
determined that the majority of cholesterol delivered to the liver
in cholesterol-rich lipoproteins is either esterified and stored or
resecreted as free and esterified cholesterol and does not alter
biliary secretion of cholesterol.
53
The work outlined in the previous chapter demonstrates that
inhibition of ACAT activity stimulates bile acid synthesis from
newly-synthesized cholesterol from excess mevalonic acid, indicating
an inter-relationship between' the two pathways open to
newly-synthesized cholesterol. Recently, work by Mackinnon et al_.
(1987), shows that HDL taken up by the receptor-mediated pathway
provides cholesterol for bile acid synthesis and cholesterol
esterification, in line with the work of Ford et al. (1985b), and
that presented in Chapter 6.
Thus one can see that recent work has produced a number of
contrasting results in the determination of the use free
cholesterol. Certainly they show that free cholesterol derived from
different sources appears to have different fates. The experiments
involving HDL show that the free cholesterol provided is used in
cholesterol esterification, but they differ in their results on the
secretion of free cholesterol. The in vivo work will be hampered by
the interactions that occur between different lipoprotein classes
and by the uptake of HDL-cholesterol by more than one pathway,
whereas the use of cultures of hepatocytes is free from these
problems but does not allow for the importance of normal plasma
interactions nor differentiation between secretion into bile of
plasma compartments. Thus different approaches to the question of
cholesterol metabolism may give contrasting results due to the
limitations of the techniques used. Furthermore each approach may
be defining certain conditions that favour the determination of
specific intracellular pools of free cholesterol which have
particular uses, indicating the existence of both complex
compartmentalization of intracellular free cholesterol and a number
of different intracellular pools of free cholesterol. It is
therefore necessary to investigate the effects of bile acid
synthesis on intracellular free cholesterol to provide a complete
study of hepatic cholesterol metabolism.
Until recently, there were no specific inhibitors of cholesterol
7a-hydroxylase so work involving the inhibition of bile acid
synthesis was not possible. The compound ketoconazole has now been
used for this purpose (Princen et al_., 1986)., but it has certain
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disadvantages. It is known to inhibit several cytochrome P-450
dependent enzymes and as such inhibits cholesterol synthesis (Gupta
et al_., 1986; Kraemer and Spilman, 1986; Baldwin, 1983). Thus
studies where the fate of newly-synthesized cholesterol is being
investigated, it is not of use. Brown et a]_., (1987) have produced a
compound, 6-azacholest-4-en-38-ol-7-one (azacholesterol), shown in
figure 2.2b, which is a specific inhibitor of cholesterol
7a-hydroxylase (Sampson et alt) 1987b). Studies on rat liver
microsomal fractions with azacholesterol show that it is effective
in inhibiting cholesterol 7a-hydroxylase by a non-competitive
mechanism, and that it does not inhibit either HMG-CoA reductase or
ACAT (Sampson et al_.; 1987b). This compound has allowed me to
determine the effect that the inhibition of bile acid synthesis has
upon esterification of cholesterol derived from newly-synthesized
cholesterol.
5.2 Effect of Azacholesterol on HMG-CoA Reductase and ACAT in Rat
Hepatocvte Monolayers
Primary cultures of hepatocytes prepared from rats fed diet Z
(Chapter 2.2) were used in these and subsequent experiments, to
ensure that bile acid synthesis was sufficiently active. 200 nm of
azachol esterol in 20pl DMSO were added to the cells (100 pM) in the
presence of 21 or 5% bovine serum albumin. HMG-CoA reductase
14
activity was assessed by addition of [ C3 acetate (3.6 pM), and
measurement of its incorporation into cholesterol and cholesterol
ester after 1 and 2 hours. Table 5.1 shows that azacholesterol has
14
no effect on the synthesis of cholesterol from [ C3 acetate nor
does it affect C^4C] acetate incorporation into cholesterol ester.
3
The above experiment was repeated using [ H] potassium oleate
(40 pM) instead of [^C] acetate, in order to assess the effect of
azacholesterol on cholesterol esterification independent of
cholesterol and triglyceride synthesis. The results here show that
azacholesterol has no effect on cholesterol esterification.
As mentioned, ketonazole inhibits cholesterol biosynthesis, acting
as a ligand for several forms of cytochrome P-450, through its
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imidazole ring system (Baldwin,1983). Evidence that azacholesterol
might also inhibit other cytochromes P-450 involved in the
conversion of lanosterol to cholesterol was looked for by examining
the sterols synthesized in cells incubated with azacholesterol and
3
[ H] mevalonic acid. In the a presence of mevalonic acid any
effects on HMG-CoA-reductase are avoided and effects later in the
pathway will be more apparent. Incubation of monolayers of rat
3
hepatocytes with C H] mevalonic acid and subsequent analysis by
t.l.c. showed that cholesterol accounted for 92 ± 6% of the total
radioactivity in mono-hydroxy sterols secreted into the culture
medium and in the presence of 100 pM azacholesterol 83 ± 9% of the
total label was located in the cholesterol fraction. These values
are not significantly different from each other under the
experimental conditions outlined, indicating that azacholesterol
does not inhibit the later oxidative steps in cholesterol synthesis.
5.3 Effect of Azacholesterol on Bile Acid Synthesis in Rat
Hepatocvte Monolayers
Azacholesterol (concentration range 0 to 500 pM) in the presence of
2% bovine serum albumin was incubated with rat hepatocyte monolayers
for 5 hours. The bile acids produced in the cells and medium were
analysed by radioimmunoassay. Figure 5.1 shows a dose-dependent
inhibition of S<jrrfVh^is^<$(1 $g.C/t&WKwi th a maximum inhibition
of approximately 90% at concentrations of 100 pM of azacholesterol
or greater. Thus, azacholesterol is an effective inhibitor of bile
acid synthesis in cultures of hepatocytes, without the concomitant
inhibition of cholesterol synthesis, as seen with ketoconazole, and
may be used as a probe for cholesterol flux to this enzyme.
5.4 Effect of Azacholesterol on the Fate of Newlv-Svnthesized
Cholesterol in Rat Hepatocvte Monolayers
Following approximately the same procedure used in Chapter 4.2 to
investigate the role played by cholesterol 7a-hydroxylase in
determining cholesterol fluxes within the hepatocyte, monolayers
were incubated with and without azacholesterol in the presence of
3
increasing concentrations of [ H] mevalonic acid (0 to 10 mM) used
Figure 5.1
Inhibition of bile acid synthesis in rat hepatocyte monolayers by
azacholesterol. Azacholesterol was added in the concentrations
shown in 10 to 50pl of DHSO to dishes containing 2.5 x 10^ cells
in 2ml DMEM containing 21 bovine serum albumin (fatty acid free).
After incubation for 5 hours, bile acids in the cells and medium
were determined by radioimmunoassay. The precision of all





to provide a substantial source of intracellular cholesterol. The
masses of cholesterol and cholesterol ester secreted into the medium
were calculated from the known specific activity of the mevalonic
acid. Although 6 molecules of mevalonic acid are used to produce
3
cholesterol, only 5 of the [ H] labels are incorporated, due to
the loss of one of them during folding of squalene. Thus the number
of moles of cholesterol produced is 1/5 not 1/6 of the number of
moles of mevalonate used as determined from the tracer.
To check this, samples with a level cholesterol determined by the
above formula were assayed for cholesterol using a fluormetric
method (Chapter 2.10). The results of this showed that the
incorporation of labelled mevalonate occurred at a rate of
approximately 4.9 moles mevalonate into 1 mole of cholesterol, only
slightly less than the theoretical value of 5:1. Also, the
cholesterol ester fraction was subjected to hydrolysis in 5N
alcoholic potassium hydroxide and subsequently re-extracted. This
showed that less than 10% of the radioactivity in the cholesterol
ester fraction was located in the fatty acyl component.
The results shown in Figure 5.2 are from studies using cells derived
from 4 separate animals. Azacholesterol did not effect cholesterol
ester secretion at any concentration of mevalonic acid. Instead, it
caused a significant increase in the secretion of free cholesterol
into the medium at all levels of mevalonate used. The mean increase
of free cholesterol secretion in the presence of the inhibitor was
2.6 ± 0.7 times the control in the absence of the inhibitor.
In conjunction with the above experiments, the bile acids produced
in the cells and the medium were measured (Table 5.2). These
results show that across all concentrations of mevalonic acid, in
the presence of azacholesterol, total bile acid synthesis is
inhibited by between 84-88%. Thus, increasing accumulation of free
cholesterol must be occurring, and this excess is seen in the
increase in free cholesterol secretion only.
Figure 5.2
Effect of azacholesterol on the secretion of free and esterified
cholesterol newly synthesised by rat hepatocyte monolayers in the
3
presence of [ H] mevalonic acid. Azacholesterol was added to give
a concentration of 200pM, producing 86% inhibition of bile acid
synthesis (Table 5.3). Labelled mevalonic acid was added at tracer
concentrations and at 1, 5 and lOmM. After 5 hours the medium was
extracted and the radioactivity in free cholesterol and cholesteryl
ester determined. Secretion of free cholesterol was significantly
increased (p<0.01) by the presence of azacholesterol by a factor of
3.48 ± 0.9 at tracer levels of mevalonate, 2.8 ± 0.4 at ImM, 2.0 ±
0.2 at 5mM and 2.0 ± 0.3 at lOmM. Secretion measurements are
expressed in units of n mole in 5 hours per 2.5 x 106 cells.
( O ) cholesteryl ester secretion in control experiments, ( • )
cholesteryl ester secreted in the presence of azacholesterol, ( ■ )
free cholesterol in control experiments, ( □ ) free cholesterol
























Experiment 0 1 5 10
Control (a) 4.05±1.08 5.13±1.44 5.19±1.46 5.39±1.39
azacholesterol (a) 0.63±0.18 0.59±0.19 0.70±0.25 0.86±0.29
Control (b) 1.00±0 1.258±0.064 1.284±0.072 1.334±0.062
azacholesterol (b) 0.156±0.024 0.151±0.041 0.177±0.044 0.213±0.038
Table 5.2
Effect of Azacholesterol on bile acid synthesis in the presence of
3
[ H] mevalonic acid in rat hepatocye monolayers. Experimental
conditions are as outlined for Figure 5.2. The data above is
presented in 2 ways: a) Raw data in n moles in 5 hours per 2.5xl06
cells; b) as normalised data, relative to the control samples with
neither mevalonate nor azacholesterol. Data is expressed as mean ±
S.D. (n=4).
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5.5 Effect of Azacholesterol and 7a-Hvdroxvcholestero1 on Bile
Acid Synthesis in Rat Hepatocvte Monolayers
7a-Hydroxychoiesterol is the product formed by the action of
cholesterol 7a-hydroxylase on cholesterol. Thus, addition of this
compound to the culture medium in the presence of azacholesterol
should overcome the inhibition of bile acid synthesis. That is
assuming that azacholesterol only affects cholesterol 7a-hydroxylase
and no other enzymes of bile acid synthesis. 7a-hydroxy cholesterol
in ethanol was added to the culture medium (concentration range: 0
to 2mM) in the presence of 100 pM azacholesterol and 21 bovine serum
albumin, and the cells cultured for 5 hours. The bile acids
produced in the cells and medium were analysed by radioimmunoassay.
Table 5.3 shows that addition of 7a-hydroxycholesterol increases
bile acid synthesis in the presence of azacholesterol indicating
that the subsequent stages in the synthesis of bile acids are not
affected.
5.6 Piscussion
In Chapter 4, I found that bile acid synthesis was increased in the
presence of excess newly-synthesized free cholesterol by inhibiting
ACAT activity. Under these conditions free cholesterol secretion
was not effected. There appeared to be a reciprocal relationship
between bile acid synthesis and cholesterol esterification. In the
experiments just presented, bile acid synthesis in the presence of a
range of mevalonic acid concentrations was inhibited by
azacholesterol; however, cholesterol esterification did not increase
in the presence of the inhibitor, indicating that the pool of
newly-synthesized free cholesterol used for bile acid synthesis was
not related to the pool of free cholesterol use for esterification.
In the presence of azacholesterol free cholesterol secretion did
increase; however, given the experimental conditions used, it is
not possible to determine if this increased secretion of free
cholesterol would be into the biliary or plasma (lipoprotein)
compartments. From this work it appears that the bile acid
synthesis and free cholesterol secretion are reciprocally related.
B1le Acid Synthesis
(p mole in 5 hours
per 2.5x106 cells) t Inhibition
a) control 4.21 ± 0.23 0
b) Azacholesterol 0.70 ± 0.10 88.4
c) Azacholesterol +
7x-hydroxycholesterol 1.22 ± 0.12 71.0
d) Azacholesterol +
7x-hydroxycholesterol 2.03 ± 0.26 51.8
Table 5.3
Effect of 7a-hydroxycholesterol on azacholesterol-induced inhibition
of bile acid synthesis. Experiments were incubated for 5 hours and
the bile acids measured in cells and medium by radioimmunoassay.
Azacholesterol was added at a concentration of 200pM and 7a-hydroxy
cholesterol was added at 2 concentrations: c) lOOpM and d) 200pM.
Results are expressed as the mean ± S.D. (n=3).
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It is possible to argue that under the conditions used, the pathway
for cholesterol esterification was saturated with excess free
cholesterol derived from mevalonate. The data presented in Table
5.2 and Figure 5.2 shows that esterification did not become
saturated until between 5 and 10 mM mevalonic acid, this is an
agreement with the data presented in Figure 4.3, where the controls
show that saturation of esterification occurs between 5 and 10 mM
mevalonic acid. Yet the effect of azacholesterol was the same at
all levels of mevalonic acid, thus supporting the above argument and
providing evidence of stricter compartmentation of the movement of
intracellular free cholesterol in the rat hepatocyte.
These results contrast with those obtained in Chapter 4, indicating
a high degree of complexity in the organisation and use
newly-synthesized free cholesterol. Both studies indicate different
interrelationships between the pathways of cholesterol use, and
different patterns of cholesterol flux. The following experiments
use an exogenous source of cholesterol, HDL,,to attempt to further
define the interactions of the various pathways.
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CHAPTER 6
The Effect of HDLg on Cholesterol Esterification
and Bile Acid Synthesis
6.1 Introduction
The synthesis of bile acids is thought to be regulated by the
availability of cholesterol (Davis et al., 1983b). Synthesis can be
stimulated by a number of sources of cholesterol derived from both
lipoproteins and the endogenous synthesis of free cholesterol
(Chapter 1.3). In the preceeding chapters I have examined the
effect of newly-synthesized free cholesterol derived from mevalonic
acid on both cholesterol esterification and bile acid synthesis. In
the proceeding chapter, I will discuss the role of cholesterol
derived from the lipoprotein subtraction HDL2 in bile acid
synthesis and cholesterol esterification.
In the rat, HDL2 contains apoproteins A-I, A-II, C-I, C-II, C-III
D and ,v_ E, cholesterol, cholesteryl ester and phospholipid, with a
very minor amount of triglyceride. It has been postulated that HDL
is involved in the transfer of cholesterol from peripheral tissues
to the liver and adrenal gland (Tall and Small, 1980). Thus, the
subtraction may be involved in regulating the size of the
extrahepatic pool of total body cholesterol and involved in the
removal of cholesterol via either its secretion into bile or its
metabolism into bile acids. Thus, it is of interest to determine
the relationship between HDL-cholesterol and bile acid synthesis.
Work by Ford e± al., (1985b), showed that HDL2 can stimulate bile
acid synthesis in mono-layers of rat hepatocytes. Recently this was
confirmed in part by the work of Mackinnon et al_.,(1987). They
showed that different types of HDL containing apo E can stimulate
bile acid synthesis and that reductive methylation of the HDL,
causing inhibition of apo E binding to both apo B/E and apo E
receptors (Hui .et al., 1986), blocked receptor-mediated uptake and
stimulation of bile acid synthesis.
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Also, apo-E rich HDL was shown to inhibit cholesterol synthesis and
cause a net accummulation of cholesteryl esters in hepatocytes.
Thus, HDL-cholesterol appears to be available for both cholesterol
esterification and bile acid synthesis.
In the following study, the effect of HDL2 on bile acid synthesis
and cholesterol esterification will be discussed using inhibitors of
ACAT and HMG-CoA reductase. 58-035 and its effects have already
been described in Chapter 4. Mevinolin, the other compound used, is
a competitive inhibitor of HMG-CoA reductase, and this of
cholesterol synthesis (Kita et aj.., 1980; Alberts et al_., 1980).
Davis et aJL, (1983a) demonstrated that in cultures of rat
hepatocytes, mevinolin inhibits bile acid synthesis, linking the
pool of newly-synthesized cholesterol with that used by cholesterol
7a-hydroxylase. Other recent work has shown that the effect of
mevinolin on cholesterol synthesis has effects on the levels of the
mRNA of both lipoprotein receptors and certain apoproteins (Ma et
al_., 1986; Monge et al_., 1985).
By using mevinolin to inhibit HMG-CoA reductase, therefore, I was
able to decrease the pool of newly-synthesized free cholesterol,
making the hepatocytes dependent on an exogenous source (HDL2) for
free cholesterol. By then inhibiting the activity of ACAT using
58-035, it was hoped that the pattern of intracellular flux so far
determined could be further elucidated by observing the uptake of
hdl2.
6.2 Effect of Mevinolin on Cholesterol Synthesis and
Esterification in Rat Hepatocvte Monolayers
Primary cultures of hepatocytes prepared from rats fed diet Z
(Chapter 2.2) were used in this and subsequent experiments.
Aliquots of mevinolin (10 to 50 pi) were added to the culture medium
in the presence of 2% bovine serum albumin giving a concentration
range of 0 to 5 pM, as described in Chapter 2.5.3. The cultures
were then incubated for 5 hours. Cholesterol synthesis and
esterification were assessed by measuring the incorporation of
[14C] acetate (3.6 pM). Figure 6.1 shows the dose-dependent
Figure 6.1
Effect of mevinolin on cholesterol synthesis and esterification in
rat hepatocyte monolayers. Mevinolin was added to the cultures in
the range of 0 to 5 pM, and synthesis and esterification determined
by following the incorporation of [14C]acetate into cholesterol
and cholesteryl ester over 5 hours. Results are in p moles in 5
hours per 2.5 x 106 cells (n-2)
(□) cholesterol; (■) cholesteryl ester.
Figure 6.1
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effect of mevinolin on both synthesis and esterification. It
inhibits cholesterol synthesis by about 70% at concentrations of 2
pM or greater, confirming the report of Pullinger and Gibbons
(1982). Other experiments by our group involving monolayer cultures
of bovine adrenocortical cells also achieved maximal inhibition at
concentrations of greater than 2 pM; however, the level of
inhibition was approximately 80% (Ochoa and Suckling, 1987). This
difference may be due to metabolic differences in the different
tissues.
In terms of cholesterol esterification, the maximum level of
inhibition is about 30%; this can be compared to 40% obtained with
the bovine adrenal cortical cells. Both results indicate that
mevinolin affects esterification, but not as markedly as synthesis.
The reason for this is simply that the cholesteryl ester contains
radioactive label in both fatty acyl and cholesterol components. As
mevinolin does not act on fatty acid synthesis, then incorporation
of label into fatty acids may actually increase due to increased
availability of substrate. The fatty acids produced will esterify
with any available cholesterol giving the effect seen. Work by
Ochoa (1986) confirmed this.
6.3 Isolation and Characterization of Lipoprotein Subtraction
HDl_2 from Rat Plasma
As described in Chapter 2.13, HDI^, a lipoprotein subtraction of
density range 1.085 - 1.21 was prepared by sequential density
gradient ultracentrifugation (Jansen £i al_., 1983), dialysed against
distilled water to remove the salts, and then reverse-phase dialysed
against carbowax. Samples of this preparation were freeze dried and
then reconstituted in a smaller volume producing a concentrated
sample for analysis by SDS-page. The results of this are shown in
Figure 6.2. The major proteins identified were apo A-I, apo A-IV
and apo E, and trace amounts of the C and D apoproteins are also
visible. Apo B is absent, indicating no contamination with LDL,
VLDL or chylomicrons. Table 6.1 shows the protein and cholesterol
composition of the subtraction, which is similar to that obtained by
Oschry and Eisenberg (1982) but differs from the results of Jansen
Figure 6.2 SDS-PAGE of HDL2 from rat plasma.
Column I: Molecular weight markers.
Column II: HDL2 apoproteins a) apo A-IV; b) apo E; c) apo A-I;
d) apo D or apo A-II; e) apo C—I/C—II/C—III
Column III: LDL sample f) apo B present as aggregates (upper band)
and as monomers (lower band).
HDL2 samples show no contamination with other lipoproteins (VLDL
or LDL) due to the absence of apo B.















34 180 0.19 0.54
4.6 25.6 0.19 0.53
Jansen et al (1984)
Table 6.1
The protein and cholesterol content of rat HDl^. The results are
compared with those of Oschry and Eisenberg (1982) and Oansen §t a_L,
(1984). FC - free cholesterol; TC - total cholesterol.
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et al., 1983. The differences are due to Jansen and co-workers
defining HDL2 as a subfraction of density range 1.112-1.128, a
narrower range than used by myself or Oschry and Eisenberg (1982),
which will have a higher amount of lipids relative to its protein
content.
Thus, 200 pi of this preparation was added per dish in subsequent
experiments to provide an approximate physiological concentration of
500 pg of HDl_2 protein per dish. (Oschry and Eisenberg, 1982;
Chapman, 1980).
6.4 Effect of HDI_2 on Cholesterol Esterifi cation in Rat
Hepatocvte Monolayers
Monolayer cultures of hepatocytes were prepared from 4 rats fed
diet Z (Chapter 2.2). The cells were pre-treated with 58-035
(200 pg per dish) or control solvent (DMSO), and mevinolin was added
(5 pM) to inhibit cholesterol synthesis. Incubations were carried
out for a total of 5 hours. During the final 2 hours, potassium
3
[ H] oleate was added (1 mM) to determine the activity of ACAT in
the cultures.
Table 6.2 shows that HDL2 stimulated cholesterol esterification by
1.32-times the control. Addition of 58-035 inhibited esterification
both in the presence and absence of HDL,; although HDI_2 in the
presence of 58-035 appears to stimulate esterification 1.33-times
when compared to 58-035 alone. These results indicate that
cholesterol derived from HDl_2 is available for esterification.
The experimental system had a homologous source for the hepatocytes
and lipoproteins, using a specific subfraction, and produced results
not previously recorded. Although a large body of work has been
done with lipoproteins, usually the cells and lipoproteins are
derived from different species, and may produce results
characteristic to their experimental systems only. The results
obtained in this study do not indicate whether uptake of HDL2 is
occurring via a receptor or non-receptor mediated mechanism. Work
by Jensen et al (1985 and 1987) determined that LDL and chylomicron
uptake by rat hepatocyte monolayers was cell-density-dependent. To
Cholesterol Esterlflcation 1
Experiment pmole/hour/2.5 x 106 cells of Control
a) control 118 ± 6.5 100
b) 58035 26 ± 3 22
c) HDL2 156 ± 9 132
d) 58-035 + HDL2 35 ± 5.5 30
Table 6.2
3
Esterification of potassium [ H] oleate in the presence of 58-035
and HDL2. Control experiments had 2ml DMEM with 21 bovine serum
albumin (fatty acid free) and 5pM mevinolin; b) as the controls with
200pg of 58035 per dish; c) as the controls with 500pg of HDL2 per
dish; d) as the controls with both HDL,, and 58-035 added.
Cultures where incubated for 3 hours and then potassium [ H]
oleate (40pm) was added for the final 2 hours. Results are
expressed as the means ± S.D. (n-4).
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ensure that the results I obtained were not affected by this, only
cultures of approximately 2.5 x 10^ cells and 1.5 mg of cell
protein per dish were used.
6.5 Effect of HDLg on Bile Acid Synthesis in Rat Hepatocvte
Monolayers
Monolayer cultures of rat hepatocytes were prepared from four rats
fed on diet Z (Chapter 2.2). The cells were pre-treated with 58-035
(200 pg per dish) or control solvent (DMSO), and mevinolin was added
(5 pM) to inhibit cholesterol synthesis. Incubations were carried
out for a total of 5 hours, and bile acids estimated in the cells
and medium by radioimmunoassay.
The basal rate of synthesis of bile acids was 2.47 ± 0.46 per
2.5 x 10^ cells. The changes caused by addition of HDI_2 and
58-035 are shown in Table 6.3 and Figure 6.3. The data shows that
HDL2 stimulates bile acid synthesis, as seen in previous work
(Ford et &]_•, 1985b) and recently shown by Mackinnon et al_. (1987).
The increase seen was about 13%. Addition of 58-035 inhibits bile
acid synthesis by about 10% compared to the controls without either
HDI_2 or 58-035. In combination 58-035 and HDL2 also inhibit
bile acid synthesis by greater than 10%. Comparison of the absolute
values of these differences by the two-tailed paired t-test showed
that the changes were significant with p < 0.05.
From these studies, it appears that cholesterol derived from HDL2
can be used by cholesterol 7a-hydroxylase, but that inhibiting ACAT
inhibits the flux of such cholesterol through to bile acid
synthesis. This indicates that prior esterification and subsequent
ester hydrolysis must occur before cholesterol derived from HDL2
can be used by cholesterol 7a-hydroxylase.
6.6 Piscussion
The combination of 58-035 and mevinolin has allowed me to study the
fate of cholesterol derived from HDL_2 and in particular its
availability for bile acid synthesis. In rat hepatocyte monolayers,
B1le Acid Syntheses
Experiment nmole per 5 hours per 2.5xl06 cells
Normalised
Data
a) control 2.47 ± 0.40 1 ± 0
b) 58-035 2.21 ± 0.40 0.893 ± 0.039
C) HDL2 2.71 ± 0.44 1.133 ± 0.039
d) 58-035 2.10 ± 0.43 0.854 ± 0.044
+ hdl2
Table 6.3
Effect of mevinolin on bile acid synthesis in rat hepatocyte
monolayers, a) control samples had 2ml DMEM with 21 bovine serum
albumin (fatty acid free) and mevinolin (5pm); b) as the controls
with 200pg of 58-035 per dish; c) as the controls with 500pg of
HDL2 per dish; d) as the controls with both HDL2 and 58-035.
Cultures were incubated for 5 hours, and bile acids were measured in
cells and medium by radioimmunoassay. Results are expressed as
nmole in 5 hours per 2.5xl06 cells ± S.D. (n=4) or as normalised
data ± S.D. (n=4). Comparisons of (b) to (a), (c) to (a), (d) to
(a), and (d) to (c) by the paired t-test showed significant
differences in cell comparisons (p<0.05). Refer to Figure 6.3.
Figure 6.3
Effect of 58-035 and HDL2 on bile acid synthesis in rat hepatocyte
monolayers, for details refer to the legend of Table 6.3. Results
are expressed as the change in bile acid synthesis from control
values i.e. change 1n nmoles in 5 hours per 2.5 x 106 cells ± S.D.
(n=4). All comparisons between controls and treated samples by the








this cholesterol is available for both esterification and
7a-hydroxylation; however, it appears that any HDl_2-derived
cholesterol used for bile acid synthesis must first be esterified
and then hydrolysed before it is available for that purpose.
Certainly, the results indicate that the immediate fate of exogenous
cholesterol is esterification, under the experimental conditions
used.
These experiments are more closely related to the in vivo situation
than those in Chapters 4 and 5, although use of a single lipoprotein
subtraction does limit the normal exchange processes that might
occur between lipoprotein classes. A preliminary experiment using a
preparation containing all the defined rat plasma lipoprotein
classes produced similar results for bile acid synthesis as obtained
by using HDL2 alone.
In my earlier experiments, intracellular transport and regulatory
mechanisms were probably saturated by the excess free cholesterol
from the added mevalonate, and uptake mechanisms and the regulatory
effect were by-passed. This system concentrates on an external
source of cholesterol and enhances the suppressant effect that
lipoprotein uptake has on HMG-CoA reductase and cholesterol
synthesis, by use of the inhibitor, mevinolin. Thus it may provide
a better estimate of the in vivo situation, when dietary cholesterol




The major aim of this body of work was to investigate and determine
the intracellular control of cholesterol metabolism in the
hepatocyte. The strategy employed involved the use of rat
hepatocytes maintained in monolayers, exposed to specific inhibitors
of different key enzymes of cholesterol metabolism and to different
sources of cholesterol. The rationale for this approach was that by
using isolated hepatocytes the extracellular environment could be
controlled, so that the effects of the inhibitors and substrates
would be more easily elucidated.
Inhibiting specific pathways of cholesterol utilization would
potentially increase the flux of cholesterol into other pathways of
cholesterol utilization; furthermore, not only are the pathways
themselves important but so too is the source of the cholesterol
used. Thus by manipulating both the pathways and sources of
cholesterol, inter-relationships that might exist between the
pathways of cholesterol metabolism and their cholesterol sources
could be elucidated.
Certainly, previous studies have attempted to define the sources of
free cholesterol used by specific pathways of cholesterol
metabolism. Schwartz et al_. (1975) and Bjorkhem and Lewenhaupt
(1979) showed that the preferred substrate for bile acid synthesis
is newly synthesised cholesterol; a view supported by the work of
Bjorkhem and Danielsson (1975) and Myant and Mitropoulos (1977).
Such findings have led to the idea that discrete pools of free
cholesterol exist within the hepatocyte which contribute different
amounts of substrate to different pathways of cholesterol metabolism
(Stange, 1987). It is of importance to realise that the term
preferred substrate when applied to bile acid synthesis means that
newly synthesised cholesterol is converted to bile acids in
preference to equilibrating with other cellular pathways, but it
does not mean that most of the bile acids are derived from this
source.
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In rats, it has been reported that only 25% of bile acids synthesised
are derived from newly-synthesised cholesterol (Long et al., 1978);
the remainder are synthesised from cholesterol derived from
lipoproteins. It is obvious from this that depending upon the
experimental conditions defined the contribution of these two
sources of substrate to the synthesis of bile acids can change. It
has been shown that cholesterol derived both from endogenous
synthesis and from certain lipoprotein fractions can be used to
produce cholesteryl esters and bile acids and can be secreted into
plasma with lipoproteins and secreted into bile (Turley and
Dietschy, 1982; Stone et al, 1987; Mackinnon et al 1987; Ford et
a]_, 1985b). As such, the term 'preferred substrate' is potentially
misleading.
The microsomal enzyme systems used in cholesterol metabolism are
unlikely to be able to determine any difference between free
cholesterol derived from either endogenous or exogenous sources.
What is most likely is that such preferences are dependent upon the
intracellular architecture of the hepatocyte. The hepatocyte, in
vivo, has 3 distinct surfaces at which different processes occur.
The cannalicular surface is involved in the secretion of bile acids
and free cholesterol into bile, and the sinusoidal surface is
involved in the uptake of certain lipoproteins and returning bile
acids and the secretion of other lipoproteins. I think it is
probable that the cell is organized in such a way that its internal
structure reflects the functions of its various aspects. Thus, bile
acid metabolism may be organized within the endoplasmic reticulum
near to or involved with the cannalicular surface and cholesterol
ester secretion in lipoproteins may be organized near the sinusoidal
surface. This leads to the idea that it would be convenient for
those secretory processes that occur at the sinusoidal surface to
derive their cholesterol from exogenous sources and those that occur
at the cannalicular surface to derive their free cholesterol from
endogenous sources. This would require the existence of different
intracellular compartments of free cholesterol, but which can and do
equilibrate with each other depending upon the metabolic state of
the hepatocyte at a given time. Certainly, other workers have
evidence for compartmentalisation both in the hepatocyte and
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intestinal cells (Stange, 1987) but no consideration has been given
to their intracellular situation or organization.
The results of the experiments presented in this thesis tend to
support the idea of compartmentalisation, when looked at as a
whole. In Chapter 4, the effect of ACAT inhibition was examined
using the compound 58-035 with mevalonic acid as a cholesterol
source. The results of the various experiments show that 58-035 is
an effective inhibitor of ACAT and does not inhibit cholesterol
7a-hydroxylase. When used in conjunction with mevalonic acid, a
stimulation of bile acid secretion occurred, but no increase in the
secretion of free cholesterol was observed, whilst cholesterol ester
secretion was inhibited. Although there was no direct quantifiable
relationship between bile acid and cholesteryl ester secretion, the
trends were in opposite directions. Thus, inhibition of ACAT
decreased cholesterol esterification, resulting in an accumulation
of free cholesterol that was used in bile acid synthesis. This
indicates that newly synthesized cholesterol can be used for both
esterification and bile acid synthesis but is not secreted.
Explained in terms of intracellular pools, as seen in figure 7.1
newly synthesized cholesterol forms a specific pool of free
cholesterol from which ACAT cholesterol and 7a-hydroxylase can
derive their substrate but which is separate from the pool of free
cholesterol used for secretion into bile or into plasma with
lipoproteins. The limitations of rat hepatocyte monolayers do not
allow for differentiation between secretion of free cholesterol into
bile or plasma because the normal anatomical relationship of the
cells has been disrupted. Thus, inhibition of ACAT accumulates free
cholesterol which is used by cholesterol 7a-hydroxylase. Possibly
further accumulation of free cholesterol would result in transfer
from pool FC^, to FC2 and then increases in free cholesterol
secretion would be seen, but this was not seen at the level of
cholesterol synthesis caused by the addition of mevalonic acid.
Figure 7.1 and subsequent figures are schematic representations of
intracellular cholesterol flux. They are independent of each other
and apply to particular experimental data or combinations of data.
In Chapter 5 the results turned out a little differently. Should


























of bile acid synthesis would have produced an increase in
esterification and no increase in free cholesterol secretion. This
was not the case. Having shown that the compound azacholesterol
does not affect the enzymes of cholesterol synthesis and
esterification , it was used in a parallel fashion to a 58-035.
Bile acid synthesis was inhibited at all levels of mevalonic acid
used, indicating that the free cholesterol normally used should be
accumulating; cholesterol esterification was not effected by this
but free cholesterol secretion was increased. Although I suspect
that this increase in secretion was into the bile, I have no proof
of this. Again, the relationship between the decrease in bile acid
synthesis and the increase in free cholesterol secretion was not
directly quantifiable. Figure 7.2 attempts to outline these
findings. Inhibition of bile acid synthesis produces an
accumulation of free cholesterol in pool FC^, which produces an
increase in free cholesterol secretion; potentially, further
accumulation may result in transfer to pool FC3 and cause an
increase in cholesterol esterification. This model allows for the
results seen and for some equilibration between pools FC1 and
FCg, and thus allows for some cholesteryl ester to be derived from
newly synthesized cholesterol. When taken together, the results so
far discussed produce an apparently contradictory picture. Figure
7.3 is an attempt to resolve these differences. Inhibition of ACAT
and cholesterol esterifications causes an accumulation of free
cholesterol in pool FC3 and thus in pool FC1 also. The degree
of cholesterol 7a-hydroxylase activity is such that any free
cholesterol accumulated is used in bile acid synthesis rather than
being transferred to pool FC2- Inhibition of cholesterol
7a-hydroxylase and bile acid synthesis causes accumulation of
cholesterol in pool FC^. If the kinetics of transfer of
cholesterol from pool FC1 favours its delivery to pool FC2 over
pool FC3, then an increase in free cholesterol secretion will be
seen. Thus, this model accounts for the combined results of
chapters 4 and 5, but does not determine, as the results do not, the
fate of the secreted free cholesterol.
Having seen the effects of an endogenous source of cholesterol, an
exogenous source was used in the experiments in Chapter 6. Results
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concerning both bile acid synthesis and cholesterol esterification
were determined, but determination of free cholesterol secretion was
not possible. Mevinolin, an inhibitor of cholesterol synthesis, was
used to ensure that the only choiesterol available was that derived
from HDL2. 58-035 was used in its capacity as an inhibitor of
ACAT. HDL2 lipoprotein sub-fraction was used as a source of
cholesterol. The results show that cholesterol derived from HDL2
increases cholesterol esterification confirming recent reports
(Mackinnon £t al_., 1987; Stone et al_, 1987). It also stimulates
bile acid synthesis. Thus, it appears that there is a connection
between these two pathways. From the models outlined in figures 7.1
- 7.3, transfer of free cholesterol from the pool used for
esterification to that used for synthesis of bile acids is to be
expected. The situation is not quite as simple as that, for
addition of 58-035 to the system caused an inhibition of cholesterol
esterification, as expected, and inhibited bile acid synthesis.
This indicates that the cholesterol derived from HDI_2 must first
be esterified and then hydrolysed before it can be used in bile acid
synthesis. This idea is supported when one compares the bile acid
secretion results obtained in the presence of 58-035 with the
control values. As cholesterol synthesis is inhibited, then bile
acid synthesis will also be inhibited due to lack of substrate
(Davis et al_., 1983a). Potentially the only sources of free
cholesterol will be the small amount being synthesized and any
stored in the pool derived from lipoproteins prior to isolation of
the hepatocytes from the rat. As flux of cholesterol does occur
from lipoprotein-derived cholesterol, then it is reasonable to
assume that the controls in these experiments are deriving some
cholesterol from the newly-synthesised pool which is depleted due to
inhibition of cholesterol synthesis, and some is from the
lipoprotein-derived pool. Addition of 58-035 will cut off this
latter source, reducing bile acid synthesis even more, as was seen.
Thus, bile acid synthesis is stimulated by cholesterol derived from
HDI_2, but the flux of this cholesterol follows an intracellular
route that is inhibited by 58-035. This is outlined in figure 7.4.
These results taken in conjunction with those of chapters 4 and 5






















and cholesterol derived from HDl_2 (the contribution of receptor
and non-receptor mediated uptake to these results is not known)
enters pool FC3 and that transfer of cholesterol between these
pools occurs via a cholesteryl ester pool. Figure 7.5 summarises
the various ideas presented here, and takes into account the
different uses of the cholesterol sources. Unfortunately, location
of the pools responsible for biliary and lipoprotein secretion of
free cholesterol is not possible, as secretion into the culture
medium cannot differentiated along those lines. Thus, the figures
show both pathways deriving from the same pool, which may not be the
case.
Comparison of this figure with figure 7.6, taken from Stange (1987)
shows that there are a number of differences between the 2 schemes.
Firstly, newly-synthesised cholesterol proceeds to both bile acid
synthesis and to a metabolically active pool of free cholesterol
from where it is esterified and secreted, rather than through the
postulated cholesteryl ester storage pool determined from my
results. Secondly, an HDL-cholesterol pool is directly linked to
bile acid synthesis as well as ester secretion, which does not fit
with the results determined in Chapter 6. Newly- synthesized
cholesterol is shown to be secreted into both bile and lipoproteins,
indirectly indicated by my results.
The compartmentalisation described by Stange is drawn from the work
of a number of investigators using different animal systems, whereas
the work presented here was done exclusively in the rat, where
differences in the end products of bile acid synthesis are seen, and
where the LDL lipoprotein fraction is metabolically insignificant.
Thus in comparison to man and other species, the rat has a
potentially different pattern of intracellular cholesterol
metabolism than the composite scheme shown in figure 7.6.
Furthermore, the literature shows that depending on the experimental
conditions used certain inter-relationships are shown in preference
to others. Certainly the picture of the intracellular organisation
of hepatic cholesterol metabolism is complex. It may well be that
the number of distinct substrate pools of free cholesterol may be












































number of products, (cholesteryl ester for storage or lipoprotein
secretion; free cholesterol for biliary or lipoprotein secretion
and use in the cell membrane; bile acid for secretion) each with a
specific precursor pool. These pools will in turn, have inputs from
a number of sources (endogenous synthesis; uptake from different
lipoproteins by receptor and non-receptor mediated routes). Each
pool in turn may be able to equilibrate with a number of the others
so that transfer of free cholesterol between the pools can occur.
However, due to physical and spatial/vectoral restraints, the
kinetics of transfer may favour certain inter-relationships. Thus,
blocking the formation of one product does not result in an even
redistribution of the accumulated free cholesterol between the other
pools, but rather to those pools which are most readily available.
In terms of the experiments defined in this thesis, a number of
refinements could be attempted to clarify the situation in the rat
hepatocyte. Repeating the experiments of chapter 6 using HDl_2
labelled in either its free cholesterol or cholesteryl ester moiety,
would provide further information concerning the partion of the
lipoprotein cholesterol between esterification, secretion and bile
acid synthesis, and further define the effects of 58-035. It would
also be of interest to examine the effects of chylomicron and VLDL
remnants and determine if cholesterol delivered by them follows the
same intracellular routes as that from HDL2, providing information
on the metabolic roles of apo B/E (chylomicron, VLDL, HDL) receptors
and apo E (HDL) receptors in cholesterol metabolism. Also,
techniques could be employed to investigate non-receptor mediated
uptake of HDL-cholesterol and determine its intracellular fate.
As stated earlier, the problem with monolayer cultures is that they
do not have the normal anatomical arrangement seen in vivo, where
the hepatocytes are in contact with 3 extracellular compartments.
Culturing of the hepatocytes on a membrane system would allow for
the maintenance of 2 separate compartments from which medium can be
removed or added. Thus, secretion into both compartments could be
examined to ascertain if the cells develop a polarity closer to that
seen in vivo, and be of use in defining the nature of the secretion
of the free cholesterol.
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The discussion has so far limited itself to work on hepatic
cholesterol metabolism and not considered any other of the tissues
in which cholesterol metabolism is of significance. In two cell
types, macrophages and bovine adrenal cortical cells, a cholesteryl
ester cycle has been postulated (Goldstein and Brown, 1977; Brown
et a]_., 1980; Oamal et a]_., 1985). Cultured macrophages have a
continuous energy-consuming (futile) cycle of esterification of
cholesterol (Brown et al., 1980), which is performed by a
non-lysosomal cholesteryl ester hydrolase and ACAT. It appears to
be interrupted by HDL which promotes removal of free cholesterol
from the cell. This leads to the idea that one of the roles of HDL
is the removal of cholesterol from peripheral tissues, in particular
macrophages, as mentioned in Chapter 1. Cultured cells of the
bovine adrenal cortex have a cycle similar to that of macrophages.
Both newly synthesised and lipoprotein cholesterol are available for
synthesis of cholesteryl ester, which can be hydrolysed and the
cholesterol used either in steroidogenesis or in cholesteryl ester
synthesis. One further cell type, the Fu5AH hepatoma cell, is said
to have such a cholesteryl ester cycle (Glick et al., 1987). Such a
situation conflicts with the compartmentalisation seen in normal
non-transformed hepatocytes, presenting a much simpler picture of
intracellular hepatic cholesterol metabolism. This conflict is
easily resolved when one considers that bile acid synthesis does not
occur Fu5AH hepatoma cells, and thus one important pathway of
cholesterol utilization is missing. As such, the cells are
primarily concerned with the synthesis and secretion of free and
esterified cholesterol with lipoproteins, and will have a different
intracellular organization of cholesterol metabolism.
Intestinal epithelial cells on the other hand show evidence for
compartmentalisation of intracellular free cholesterol, recently
reviewed by Stange (1987). In this case, 2 pools, one of absorbed
free cholesterol, the other of newly-synthesised cholesterol,
contributes to a third pool, which provides free cholesterol for
both a cell membrane pool and a chylomicron pool. Also, the
absorbed cholesterol pool provides the substrate for cholesteryl
esterification and secretion. In this model, stricter roles for the
various sources of free cholesterol exist than occur in any model
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seen for the hepatocyte; furthermore, the pattern of intracellular
cholesterol flux is apparently less complex than that of the
hepatocyte. Thus, the organisation of intracellular cholesterol
metabolism differs depending on the cell type and the complexity of
its function.
The importance of the cell types mentioned, in particular
hepatocytes, in the metabolism of cholesterol, is seen when one
considers certain disease states related to the excess accumulation
of cholesterol, such as atherosclerosis. Intestinal cells are the
absorption site of dietary cholesterol; macrophages are involved
directly in the formation of atherosclerotic lesions via their
transformation into foam cells; and adrenocortical and other
steroidogenic tissues metabolise cholesterol to specific products.
Each of these is involved in cholesterol homeostasis. The liver,
also involved in cholesterol homeostasis, is the only site of the
metabolism of cholesterol to bile acids and their subsequent
excretion. Thus, it represents the only significant route for the
removal of cholesterol and the decrease of the total body pool of
cholesterol, potentially preventing accumulation of excess steroid.
Understanding intracellular hepatic cholesterol metabolism may show
a way to more directly controlling cholesterol homeostasis,
providing a route for medical intervention in certain disease states.
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"And on the pedestal, these words appear:
My name is Ozymandias, King of Kings,
Look on my Works, ye Mighty and despair!
Nothing beside remains..."
Shelley
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The role of acyl-CoA: cholesterol acyltransferase in the metabolism
of free cholesterol to cholesteryl esters or bile acids
in primary cultures of rat hepatocytes
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Sandoz compound 58-035 has been shown to inhibit acyl-CoA: cholesterol acyltransferase activity in a
variety of cell types. We have shown that it does not inhibit rat liver microsomal cholesterol 7a-hydroxylase,
the rate-limiting enzyme of bile-acid synthesis, but it does inhibit acyl-CoA: cholesterol acyltransferase in
both the microsomal fraction and in rat hepatocyte monolayers. To test the role of acyl-CoA: cholesterol
acyltransferase in these cells, monolayers were incubated over 5 h in the presence and absence of 58-035 and
in the presence of increasing amounts of mevalonic acid to provide a source of cholesterol. The addition of
mevalonic acid increased the secretion of bile acids by the cells, and this was further increased by the
addition of 58-035. The secretion of cholesteryl esters was conversely inhibited by the addition of 58-035.
The results help define the role of acyl-CoA: cholesterol acyltransferase in determining the fate of
intracellular cholesterol.
Introduction
The liver presents one of the most complex
patterns of intracellular cholesterol metabolism of
all tissues. It can take up cholesterol from the
blood in lipoproteins derived from endogenous
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sources (LDL, IDL) and from exogenous sources
(chylomicron remnants) [1], The liver is also an
important tissue for synthesis of cholesterol [2].
Cholesterol is secreted from the liver in the free
and esterified form in nascent lipoproteins, par¬
ticularly VLDL. It is also secreted into bile in
combination with phospholipids and with bile
acids, which are themselves synthesised from
hepatic cholesterol [3]. The existence of these dif¬
ferent metabolic roles for hepatic cholesterol raises
the possibility that certain discrete intracellular
pools of cholesterol are present that are specific
for one or other of these functions. There is some
evidence that such pools exist and interact. For
example the pool of cholesterol that provides the
free sterol secreted into bile appears to be related
to the substrate pool for esterification of
cholesterol [4,5]. In other cases, for example the
cholesterol that serves as substrate for bile-acid
0005-2760/87/S03.50 © 1987 Elsevier Science Publishers B.V. (Biomedical Division)
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synthesis, the source of cholesterol is less clear.
Newly synthesised cholesterol has often been re¬
garded as the ' preferred' source [6]. More recently,
lipoproteins have been shown to provide substrate
cholesterol for bile-acid synthesis in the rat [7]. In
man either the free [8] or esterified [9] form may
be important. In rats and in many other animals,
especially in the fed state, the cholesteryl ester
that is secreted into the blood from the liver is
formed under the catalysis of the microsomal en¬
zyme acyl-CoA: cholesterol acyltransferase [10].
This is a key enzyme in the intracellular exchanges
of free cholesterol in the liver, since it determines
the fate of a certain proportion of the cellular
cholesterol.
Recently, a useful tool, the Sandoz compound
58-035, has become available for studying the role
of this enzyme in cellular cholesterol metabolism.
It has been shown to inhibit acyl-CoA: cholesterol
acyltransferase activity in hepatoma cells, gut cells,
ovarian Cells, macrophages and in bovine adrenal
cortical cells [11-15]. We have used this com¬
pound in studies of the control of cholesterol
movement in the adrenal cortex. By, inhibition of
either cholesterol esterification (58-035) or
mitochondrial oxidation of cholesterol, we have
been able to describe the changes in the pathway
followed by cholesterol derived from lipoproteins
in these cells when they are stimulated. with a
tropic hormone [14,16], In this paper we describe
the first stages of the parallel studies of the more
complex pathway open to intracellular cholesterol
in the liver [10]. In these new studies esterification
of cholesterol is again inhibited by 58-035, and
oxidation of cholesterol (in studies to be reported
elsewhere) by a new specific inhibitor of cholesterol
7a-hydroxylase [17]. Because several lipoprotein
particles can be taken up by the liver, by mecha¬
nisms not limited to receptor-mediated endocyto-
sis [18], and because the effects of 58-035 have not
yet been characterised in rat hepatocytes in mono¬
layer culture, we chose first to study the effect of
58-035 on the fate of cholesterol newly synthesised
within the liver from mevalonate. This is an ap¬
proach that has often been used in studies of
cholesterol esterification in liver [19,20] and it has
also been useful in describing the dependence of
bile-acid synthesis on substrate supply in rat
hepatocytes [21,22], We believe that this is a rea¬
sonable first approach, although it is not as close
to the physiological prototype as a study with
defined lipoprotein fractions. However, the effects
of mevalonic acid on cholesterol metabolism are
broadly understood [19-22], whereas the situation
with regard to lipoproteins is not. The present
paper, therefore, describes the effects of 58-035 on
hepatic cholesterol metabolism in the presence of
mevalonic acid as a simple first step to set the
scene for a broader study to follow.
Materials and Methods
Preparation of hepatocytes
Rat hepatocytes were prepared by the col-
lagenase perfusion technique described previously
[7] from rats fed either a control diet or the same
diet containing 4% (w/w) cholestyramine.
Effect of 58-035 on cholesteryl ester formation in
monolayers of rat hepatocytes
The effect of the acyl-CoA: cholesterol acyl¬
transferase inhibitor 58-035 on cholesteryl ester
formation in these cells was determined in two
ways. Firstly, after adhesion of the cells to the
dishes the medium was changed to 2 ml supple¬
mented Dulbecco's modified Eagle's medium [7]
and the cells incubated overnight. The medium
was then changed to 2 ml supplemented
Dulbecco's modified Eagle's medium [7] contain¬
ing 20% (v/v) foetal calf serum. 58-035 was added
in solution in dimethyl sulphoxide (20 /xl) to give a
final concentration of up to 100 jag/ml inhibitor.
After a further 2 h incubation the medium was
removed and the cells were washed in 0.1 M
potassium phosphate buffer (pH 7.4). The cells
were then scraped off the dishes with a rubber
policeman using 2 X 0.5 ml aliquots of potassium
phosphate buffer. The resulting suspensions were
individually homogenised, 10 jul were removed for
analysis of protein, and the remainder transferred
to Eppendorf tubes and centrifuged at 8 800 X g
in a microfuge for 5 min. 100 jul of bovine serum
albumin (fatty-acid free) and glutathione solution
in potassium phosphate buffer (each 10 mg/ml)
was added to 850 jul of the supernatant. After 30
min preincubation at 37 °C [14C]oleoyl-CoA (150
jul, final concentration 42 jaM) was added and the
mixture incubated for 1 min. The reaction was
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stopped by the addition of 2 ml methanol. Extrac¬
tion and analysis of products was carried out as
described previously [23].
In the second group of experiments the forma¬
tion of cholesteryl ester was measured directly in
the cells. After 2 h preincubation in the presence
of 58-035 (100 or 200 jug dish added in dimethyl
sulphoxide) or dimethyl sulphoxide alone the
medium was removed and 2 ml supplemented
Dulbecco's modified Eagle's medium containing
5% bovine serum albumin and potassium
[3H]oleate (40 juM, 50 dpm/pmol) was added.
25-Hydroxycholesterol was added to some incuba¬
tions as a solution in ethanol (10 mg/ml) to give a
final concentration of 10 jag/ml medium [14],
Potassium [3H]oleate was prepared from oleic acid,
following Ref. 20. After 1.5 h incubation, the
medium was removed and the cells scraped off
into potassium phosphate buffer. Both the cells
and the media were extracted with chloroform/
methanol (2:1 (v/v)) and the radioactivity in the
cholesteryl ester fraction was determined as
described previously [23].
Effect of 58-035 on secretion of bile acids and
cholesteryl ester by monolayers of rat hepatocytes
After the cells had adhered to the culture dishes
the medium was replaced with 2 ml supplemented
Dulbecco's modified Eagle's medium containing
2% w/v bovine serum albumin. 200 jag 58-035 in
20 jal dimethyl sulphoxide was added to some of
the dishes; either dimethyl sulphoxide (20 jal) or
no additions were amde to control dishes. The
dishes were further incubated for 2 h. After this
the medium was replaced with 2 ml supplemented
Dulbecco's modified Eagle's medium containing
0-10 mM mevalonolactone and without bovine
serum albumin. After a 5 h incubation the media
were removed and stored for determination of bile
acid and cholesteryl esters. The cells were scraped
off the plates into 1 ml potassium phosphate
buffer, and a homogenate of this mixture was used
for protein determination.
Conjugated cholic, chenodeoxycholic and /3-
muricholic acids were determined in the medium
by radioimmunoassay [24-26]. Cholesterol and
cholesteryl ester in the medium were determined
fluorimetrically [27], In other experiments the dis¬
tribution of cholesterol, cholesteryl ester, tri-
acylglycerol and phospholipid was determined in
the pooled media from several culture dishes. The
media were separated into fractions of different
buoyant density [28], and the lipids in the various
fractions analysed by fluorimetry for cholesterol
and cholesteryl ester and on a centrifugal auto-
analyser for triacylglycerol and phospholipid.
SDS-polyacrylamide gel electrophoresis [29] was
used to characterise the apoproteins present in the
lipoprotein fraction d < 1.03 g/ml.
Cholesterol 7a-hydroxylase activity was de¬
termined, using [14C]cholesterol added to a micro¬
somal preparation of rat liver [30], Protein was
determined by the dye-binding method of Brad¬
ford [31]. Acyl-CoA: cholesterol acyltransferase
activity was determined in microsomal fractions of
rat liver as described previously [23], using oleoyl-
CoA.
Collagenase, galactose, gentamycin sulphate,
insulin and mevalonolactone and bovine serum
albumin fraction V powder were obtained from
Sigma (Poole, U.K.). Other preparations of col¬
lagenase and bovine serum albumin were obtained
from Boehringer-Mannheim (London, U.K.). The
bovine serum albumin was pretreated with char¬
coal to remove bile acids. 25-Hydroxycholesterol
was purchased from Steraloids (Croydon, U.K.).
Dulbecco's modified Eagle's medium and penicil¬
lin/streptomycin were obtained from Gibco
Europe (Paisley, U.K.). Non-essential amino acids
and foetal calf serum were obtained from Flow
Laboratories (Irvine, U.K.). Foetal calf serum was
heat-inactivated by incubation at 56 °C for 30
min. Cholestyramine (Cuemid) was supplied by
Bristol-Myers (Uxbridge, U.K.). Percoll was a
product of Pharmacia (Milton Keynes, U.K.). Ra¬
diochemicals were obtained from Amersham In¬
ternational (Amersham, U.K.). 58-035 (3-(decyl-
dimethylsilyl)-«-[2-(4-methylphenyl)-l-phenyleth-
yl]propanamide) was a gift of Dr John Heider,
Sandoz Inc., East Hanover, NJ, U.S.A.
Results
Effect of 58-035 on acyl-CoA: cholesterol acyl¬
transferase activity in vitro
Since the effect and specificity of 58-035 had
not previously been reported in rat liver, we car¬
ried out preliminary experiments to test the effect
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of 58-035 on acyl-CoA: cholesterol acyltransferase
activity in rat liver microsomes in vitro. 58-035
added in solution in acetone or dimethyl sulpho-
xide inhibited acyl-CoA: cholesterol acyltrans¬
ferase activity to 12% of controls containing the
solvents at a concentration of 0.6 jag 58-035 to 500
mg microsomal protein. Acyl-CoA: cholesterol
acyltransferase activity can be increased in vitro
by a variety of methods, by 25-hydroxycholesterol,
by an ATP-dependent process and by addition of
free cholesterol in a number of ways [10]. In each
case 58-035 inhibited the 'activated' system to
levels similar to those of control assays containing
58-035 and microsomes alone. Thus, 58-035 is able
to inhibit acyl-CoA: cholesterol acyltransferase
activity whatever the state of the enzyme in vitro,
and this is consistent with the inhibitor's acting
directly on the enzyme. 58-035 did not inhibit rat
liver microsomal cholesterol 7a-hydroxylase at
concentrations equivalent to those capable of in¬
hibiting cholesterol esterification or at concentra¬
tions 40-times that. 58-035 is also known not to
inhibit cholesterol synthesis in bovine adrenal
cortical cells [14], although this point is not im¬
portant in the present work, since most of the
studies were carried out in the presence of
mevalonic acid, to provide a substantial supply of
intracellular cholesterol.
Effect of 58-035 on cholesterol esterification in rat
hepatocyte monolayers
We then carried out parallel experiments in
monolayers of rat hepatocytes to determine
whether 58-035 could enter the cells and effi¬
ciently inhibit cholesterol esterification. The in¬
hibitor was most effectively presented to the cells
as a solution in dimethyl sulphoxide (up to 200
jug/dish in 20 jiil) in the presence of bovine serum
albumin (2-5% (w/v)). Under these conditions
the inhibition of the formation of cholesteryl
[14C]oleate from [14C]oleoyl-CoA in the 8800 X g
supernatant prepared from the cells followed the
dose-response curve shown in Fig. 1. These ob¬
servations were confirmed by measuring the incor-
potation of potassium [3H]oleate into cholesteryl
oleate in the intact cells over 1.5 h (Table I). Table
I also shows that addition of 25-hydroxy-
cholesterol to the cells stimulated formation of
cholesteryl ester [19]. The stimulation by 25-hy-
Fig. 1. Dose-response curve for the inhibition of acyl-
CoA: cholesterol acyltransferase activity in the 8 800 X g super¬
natant prepared from monolayers of rat hepatocytes treated
with the inhibitor 58-035. See Materials and Methods for
experimental details. ACAT, acyl-CoA: cholesterol acyl¬
transferase.
droxycholesterol was inhibited by 58-035, but in
each case 25-hydroxycholesterol increased the ex¬
tent of cholesteryl ester formation by the same
amount, about 2.8-fold. In these experiments and
those that follow, the solvent, dimethyl sulph¬
oxide, had no effect on cholesteryl ester formation
or secretion or bile-acid synthesis and secretion.
TABLE I
INCORPORATION OF POTASSIUM [3H]OLEATE INTO
CHOLESTERYL ESTER IN MONOLAYERS OF RAT
HEPATOCYTES IN THE PRESENCE OF 58-035 AND 25-
HYDROXYCHOLESTEROL
Monolayers of rat hepatocytes were incubated in the presence
of potassium [3H]oleate with 58-035 and 25-hydroxy¬
cholesterol under the conditions described in Materials and













2 Control + dimethyl sulphoxide
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4 2 + 25-Hydroxycholesterol
5 1 +100 jug 58-035
6 2 + 200 jig 58-035
7 5 + 25-Hydroxycholesterol
8 6 + 25-Hydroxycholesterol
5
MEVALONIC ACID (mil)
Fig. 2. Effect of 58-035 on the secretion of bile acids by
monolayers of rat hepatocytes in the presence of increasing
concentrations of mevalonic acid. The points show the bile
acids secreted relative to control and are the mean + S.E. from
nine independent experiments. Comparison of the paired data
for each animal by the Wilcoxon signed rank test showed a
significant increase in bile-acid secretion in the presence of
58-035 over controls at 5 mM mevalonic acid (P = 1.95%) and
at 10 mM (P = 3.9%). ■, control; •, 58-035 added. * Means
are significantly different (P < 5%) from control (calculated by
Student's /-test on the normalised data).
Changing the medium from that containing the
inhibitor to fresh medium without inhibitor and
further incubation of the cells for up to 16 h
followed by preparation of the 8 800 X g super¬
natant fraction and assay of acyl-CoA; cholesterol
acyltransferase activity showed that the inhibition
was still observable (data not shown). It appears
that the highly hydrophobic 58-035 remains asso¬
ciated with the cells even when the donor medium
is removed. These studies and those described
above together with published work [11-15] show
that 58-035 is a suitable compound for studying
the effects of inhibition of cholesterol esterifica-
tion in monolayers of rat hepatocytes.
Effect of 58-035 on secretion of bile acids by rat
hepatocyte monolayers
We have shown previously that monolayers of
rat hepatocytes secrete cholate, chenodeoxycholate
and /8-muricholate over periods of up to 18 h in
culture. The greatest rate of synthesis is observed
over the first 5 h of incubation. The three bile
acids measured by radioimmunoassay represent
over 90% of those synthesised by the hepatocytes
[32], The amount of bile acids secreted by a pre¬
paration of hepatocytes can be increased by feed¬
ing the rats from which the cells are to be pre¬
pared a diet containing the bile-acid-binding resin
cholestyramine [32].
There is evidence from studies in isolated cells
[7,21] and also in microsomal preparations [6] that
the rate of bile-acid synthesis, controlled by the
activity of cholesterol 7a-hydroxylase, is depen¬
dent on the supply of substrate cholesterol. To
investigate the role of acyl-CoA: cholesterol acyl¬
transferase in the rat hepatocytes, we therefore
incubated monolayers with and without 58-035 in
the presence of increasing concentrations of
mevalonic acid to provide a substantial intracellu¬
lar source of cholesterol. The secretion of the three
bile acid into the culture medium was measured
after 5 h by radioimmunoassay. Nine animals
were independently studied with basal rates of
bile-acid synthesis ranging from 0.2 nmol/mg cell
protein to 4 nmol in 5 h, depending on the diet
used. Because of this wide variation the results
were treated in two ways. Firstly the amounts of
the bile acids secreted in 5 h were expressed as the
increase in bile-acid secretion over that obtained
with the control incubations in which no 58-035 or
mevalonate had been added. The mean of these
values was calculated and statistical significance
between the incubations with 58-035 present and
absent was evaluated using Student's /-test. The
results of this analysis are shown in Fig. 2. Alter¬
natively, the data from paired incubations with
and without 58-035 were compared directly by the
Wilcoxon signed rank test. The results of this
comparison are given in the legend to Fig. 2.
Whichever method of analysing the results for
significance was chosen, 58-035 was found to cause
a highly significant increase in the secretion of bile
acids from the cells at concentrations of mevalonic
acid over 5 mM (1.26-times control at 5 mM and
1.25-times at 10 mM). No significant increase was
observed in the absence of mevalonic acid. A
small increase in the secretion of bile acids was
observed before [21]. The increase in bile-acid
secretion due to 58-035 was significant, taking all
the nine animals studied as a group, but it was
most marked in the situations where the basal rate
of bile-acid secretion was high.
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Effect of 58-035 on the secretion of cholesteryl esters
by monolayers of rat hepatocytes
To parallel the observations on the secretion of
bile acids just outlined, we examined the secretion
of cholesteryl ester into the medium in the same
preparations of cells as those studied for bile-acid
secretion. Firstly we characterised the nature of
the lipoprotein particles in which the cholesteryl
ester was secreted from the cells. Based on previ¬
ous work, it was thought to be likely that the
cholesteryl ester would mainly be secreted into
particles of density less than 1.03 [28]. This frac¬
tion was prepared by ultracentrifugation of media
from incubations of rat hepatocyte monolayers for
over 5 h. The fraction of density less than 1.03 was
analysed for lipid composition and for
apolipoproteins by SDS-polyacrylamide gel elec¬
trophoresis. The lipid composition was found to
be triacylglycerol: phospholipid : free cholester¬
ol : cholesteryl ester 100 : 20 : 10 : 14 and the
apolipoproteins, apo-B, apo-C and apo-E were
detected on the gels. The amount of cholesteryl
ester in this fraction was about 90% of the total in
the medium.
In the presence of mevalonic acid the secretion
of cholesteryl ester would be expected to increase
[19,20]. This was observed and the secretion of
ester now was found in other lipoprotein density
fractions as well as d < 1.03. 27% of the total
cholesterol ester in the medium was found in the
d < 1.03 fraction. A further 22% was present in the
range 1.03-1.08 and the remaining 51% in the
range 1.08-1.23. Thus, all the cholesteryl ester
secreted from the cells was present in a lipoprotein
fraction. As with the secretion rates of the bile
acids, the rates of secretion of cholesteryl ester by
0 I 2 3 4 5 6
MEVALONIC ACID (mM)
Fig. 3. Effect of 58-035 on the secretion of cholesteryl ester by monolayers of rat hepatocytes in the presence of increasing
concentrations of mevalonic acid. The points show the cholesteryl ester secreted relative to control and are the mean + S.E. of eight
independent experiments. Comparison of the paired data for each animal by the Wilcoxon signed rank test showed a significant
decrease in the secretion of cholesteryl ester over controls at 0 mM mevalonic acid (P = 0.78%), 1 mM (P = 3.9%) and 5 mM
(P — 3.1%), ■. control; •, 58-035 added. * Means are significantly different (P < 5%) from control (calculated by Student's Mest on
the normalised data).
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the cells varied over a wide range, from 10.4 to
0.36 nmol/mg cell protein in 5 h. The amounts of
cholesteryl ester secreted by the cells in the pres¬
ence and absence of 58-035, and of varying con¬
centrations of mevalonic acid were compared in
the same way as the bile-acid data using normal¬
ised data, and by the Wilcoxon signed rank test
(Fig. 3). Secretion of cholesteryl ester was in¬
creased by mevalonic acid 1.5-fold, as would be
expected. The presence of 58-035 inhibited the
secretion of cholesteryl ester at concentrations of
mevalonic acid from 0 to 5 mM (42% of control at
zero mevalonate and 37 °C at 5 mM). The effect
of 10 mM was not significant. Since inhibition of
acyl-CoA: cholesterol acyltransferase is about 80%
complete in these experiments (Fig. 1), any effect
at 10 mM mevalonic acid was probably overcome
by the large excess of free cholesterol present in
the cells.
No effect of 58-035 was observed on the secre¬
tion of free cholesterol. The free cholesterol
secreted in the presence of 58-035 in all the experi¬
ments was 1.14 + 0.35 (S.D., n = 21) of the corre¬
sponding incubations without 58-035. The free
cholesterol secreted from monolayer cultures of
hepatocytes could derive from either secretion into
bile or plasma compartments. Because of this am¬
biguity inherent in the monolayer technique, no
firm conclusions can be drawn from this observa¬
tion.
In combination, the experiments in Fig. 2 and 3
show that inhibition of acyl-CoA: cholesterol
acyltransferase causes an increase in bile-acid
secretion and a corresponding decrease in secre¬
tion of cholesteryl esters in those cells which had a
high availability of free cholesterol.
Discussion
The use of the acyl-CoA : cholesterol acyltrans¬
ferase inhibitor 58-035 in the experiments
described here has allowed a comparison of the
availability of free cholesterol in the hepatocyte
for esterification and secretion in lipoproteins with
its use as a precursor for bile acids. It is clear that
under the present conditions the substrate pools
of cholesterol for bile-acid synthesis and for
esterification can interact: they may be regarded
as part of the same large intracellular metaboli-
cally active pool. The increase in bile-acid synthe¬
sis in the presence of 58-035 does not show a
molar correlation with the decrease in the secre¬
tion of ester, although clearly the broad trends are
in opposite directions. Other studies in rat
hepatocytes show that the synthesis of bile acids is
positively correlated with the amounts of free
cholesterol in the cells, but negatively correlated
with the amounts of cholesteryl ester present [33].
This is in agreement with the pattern shown by
the current studies where the increased supply of
free cholesterol caused by the inhibition of acyl-
CoA: cholesterol acyltransferase leads to an in¬
creased production of bile acids. Other recent
studies [34,35] relate to the question of substrate
supply for cholesterol esterification and bile-acid
synthesis in rat liver. These are long-term in vivo
studies (several days) and cannot be compared
with the present work where processes occurring
in a few hours and under special conditions were
examined. Many studies do lead to the conclusion
that in liver the substrate pools for bile-acid
synthesis and cholesterol esterification are prob¬
ably not saturated [6,10]. This would also appear
to be the case in our cells under the conditions of
these experiments, since the addition of mevalonic
acid alone increased the secretion of both prod¬
ucts.
The pattern of the intracellular cholesterol flux
described here is similar to that we observed in
parallel experiments in the bovine adrenal cortical
cells [14], The excess cholesterol produced in the
cells is used according to the capacity of the
enzyme systems that are present. However, it is
clearly difficult to extrapolate from the present
data to the situation in vivo. The present data
demonstrate the possibilities for the movement of
free cholesterol within the hepatocyte. It is of
particular importance to discover whether similar
effects occur with cholesterol derived from lipo¬
proteins. The result may well differ for lipopro¬
teins of different sources and density ranges, and
with the mechanism of uptake of cholesterol and
cholesteryl ester.
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The effect of inhibition of cholesterol esterification on the fate of
cholesterol derived from HDL in rat hepatocyte monolayers
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Rat HDL2 is known to stimulate bile acid synthesis in rat hepatocyte monolayers. The intracellular fate of the cholesterol
derived from the HDL2 was studied using the inhibitor of cholesterol esterification, Sandoz compound 58-035. Rat HDL2
added to rat hepatocyte monolayers caused a stimulation of cholesterol esterification of 32%. This stimulation could be
inhibited by 58-035. A small significant increase in bile acid synthesis was also observed in cells in the presence of HDL2,
confirming our earlier observations. 58-035 prevented this increase. These observations imply that cholesterol entering
the cell from HDL2 is first esterified and can only enter the substrate pool for bile acid synthesis after subsequent intracel¬
lular hydrolysis.
Bile acid; HDL; Acyl-CoA:cholesterol acyltransferase; Lipoprotein; Cholesterol metabolism; (Rat hepatocyte)
1. INTRODUCTION
Lipoproteins are taken up by cells by a variety of
mechanisms. Of these the best characterised is
receptor-mediated endocytosis by the LDL
pathway [1]. In some tissues non-receptor
mediated uptake also contributes, and mechanisms
in which the apoprotein of HDL is taken up at a
slower rate than its lipid core have also been
described [2]. In all these cases some of the
metabolic consequences of uptake of cholesterol
are known but it is not clear whether cholesterol
entering a cell by one of these routes is constrained
to a particular cellular pathway or whether it can
immediately equilibrate with the cellular
metabolically active pool [3,4], In some tissues,
such as the bovine adrenal cortex, it has been
possible to demonstrate the route followed by
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cholesterol derived from LDL within the cell under
different metabolic conditions [5,6]. In other
tissues, such as the liver, there are indications that
there may be compartmentation of cholesterol
metabolism [3,4] but there has been no direct
evidence of this.
Free cholesterol derived from lipoproteins in the
liver may have a number of fates. This free
cholesterol may be secreted into the plasma as a
component of lipoproteins or, with phospholipid
and bile acids, into bile. Alternatively it may be us¬
ed as a substrate for bile acid synthesis or be
esterified by the enzyme acyl-CoA: cholesterol
acyltransferase (ACAT) [4]. We demonstrated a
few years ago that a rat lipoprotein fraction, HDL2
can stimulate the production of bile acids in
monolayers of rat hepatocytes [7], Here we show
that this stimulation can be completely blocked by
the inhibition of cholesterol esterification in the
cells by the Sandoz compound 58-035.
2. MATERIALS AND METHODS
Rat hepatocyte monolayers were prepared by collagenase per¬
fusion of livers obtained from rats that had been maintained on
Published by Elsevier Science Publishers B. V. (Biomedical Division)
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a diet containing 4% cholestyramine to induce bile acid syn¬
thesis. The culture conditions and the measurement of bile acids
by radioimmunoassay were carried out as described [8]. The
ACAT inhibitor, Sandoz compound 58-035, provided by Dr J.
Heider (Sandoz Research Institute, E. Hanover, NJ), was add¬
ed to cell monolayers dissolved in dimethyl sulphoxide (200 fig
per 2 ml dish in 20 fi\ dimethyl sulphoxide [9]), and cholesterol
esterification was measured by determining the incorporation
of [3H]oleic acid into cholesteryl esters [9].
Hepatocyte monolayers were prepared independently from 4
rats. The cells were pretreated with 58-035 or control solvent
(dimethyl sulphoxide) as described [9]. Mevinolin (obtained
from Mr A. Alberts, Merck Sharp & Dohme, Rahway, NJ) was
added (5 /*M) to remove the effect of endogenous cholesterol
synthesis, making the cells more dependent on added lipopro¬
tein. Incubations were carried out for 5 h and bile acids
estimated in both cells and medium as described in [7]. In some
of the incubations [3H]oleic acid was added to estimate
cholesterol esterification during the final 2 h of incubation [9].
HDL2 was added to incubations at a concentration of 500 fig
per dish, about that corresponding to the plasma concentration
in rats [7,10]. The lipoprotein fraction was prepared by stan¬
dard centrifugation techniques from rat plasma [11], the frac¬
tion of density 1.085-1.210 being used for the experiments.
This fraction contained 251 /zg protein, 160 fig cholesteryl ester
and 20 fig free cholesterol in 100 fi\ of the preparation that was
added to cells. The composition of this fraction is close to that
reported in [12], Analysis of this fraction by SDS-gel elec¬
trophoresis showed that apo-A-I was the main apolipoprotein
present. There were also significant amounts of apo-E and apo-
A-IV and trace amounts of apo-C-II and apo-D. No apo-B was
present.
3. RESULTS AND DISCUSSION
The addition of HDL2 to the cells in culture
caused an increase in the synthesis of cholesteryl
ester of 32% (table 1). Esterification could be in¬
hibited by the addition of 58-035, as we had
observed previously [9]. This increase, which is
significant (p < 0.01), provides a scale over which
the changes due to HDL2 can be compared. The
data in table 1 suggest that the cholesterol present
in the HDL2 was able to enter the cell and increase
the supply of substrate to the pool for esterifica¬
tion, which is probably not saturated under normal
conditions [4]. In other experiments we have
shown that HDL2 labelled with [14C]cholesterol in
either the unesterified or esterified form can enter
rat hepatocytes in monolayer culture and provide
substrate for bile acid synthesis (Ford, R.P., un¬
published). In related work in vivo and in the per¬
fused liver Stone et al. [13] have shown that
cholesteryl ester-rich rat HDL can stimulate
hepatic ACAT activity by 45%, which is a com¬
parable increase to that found in our experiments
Table 1
Esterification of [3H]oleate by rat hepatocyte monolayers in the
presence of 58-035 and rat HDL2
Additions pmol cholesteryl ester formed
1. Control (5 fiM mevinolin) 237 ± 13
2. 1 + 58-035 52 ± 6
3. 1 + HDL2 312 ± 18
4. 2 + 58-035 69 ± 10
Cells (4 independent preparations) were incubated in the
presence of additions for 5 h. During the last 2 h of this period
potassium [3H]oleate was added. At the end of the incubations
the lipids were extracted and the radioactivity in the cholesteryl
esters determined after separation on silica Bond-Elut columns.
Data are the means ± SD of 4 independent preparations assayed
in duplicate culture dishes
in hepatocytes. However, unlike the experiments in
cell culture [7,10], no increase in bile salt synthesis
was observed.
We have shown previously that 58-035 does not
inhibit cholesterol 7cr-hydroxylase [7] or HMG-
CoA reductase [5]. Other enzymes of cholesterol
metabolism in certain cell types (e.g. cholesteryl
ester hydrolase in bovine adrenal cortical cells) are
also unaffected by 58-035 [5]. In the present ex¬
periments cholesterol synthesis in the cultured
hepatocytes was inhibited by mevinolin, so any in¬
direct effects of 58-035 on HMG-CoA reductase
activity over the 5 h incubation period would not
be of significance. The basal rate of synthesis and
secretion of bile acids by the cells in 5 h was 2.47
± 0.46 nmol per 2 x 106 cells. The changes caused
by the addition of HDL2 and 58-035 in each of the
4 animals studied (and the corresponding mean
values) are shown in fig. 1. Comparison of the ab¬
solute values from which these differences were
calculated by the two-tailed paired (-test showed
that the changes were significant with p < 0.05.
The data in fig.l show that, in addition to caus¬
ing an increase in cholesterol esterification, the
added HDL2 caused a small but significant
stimulation of bile acid synthesis. This observation
was reported previously from our group [7] and
has been confirmed under slightly different ex¬
perimental conditions [10]. Thus cholesterol de¬
rived from the added lipoprotein was available as
substrate for both ACAT and cholesterol la-
hydroxylase, the initial step in bile acid synthesis
[4].
Free cholesterol is required as the substrate for
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rat 1
58-035 HDL, 58-035*HDL2
Fig.l. Change in bile acid synthesis by rat hepatocyte
monolayers in the presence of mevinolin, 58-035 and rat HDL2.
Rat hepatocytes were incubated with the additions shown under
the conditions described in section 2. The data shown are the
changes in bile acid synthesis compared with the control value
for preparations of cells from each of 4 rats. Error bars show
the standard deviation of triplicate determinations of the
secreted bile acids by radioimmunoassay [8],
cholesterol 7er-hydroxylase [14]. Therefore
cholesterol entering the cell as cholesteryl ester
must be hydrolysed at some stage before it enters
the substrate pool for synthesis of bile acids. Free
cholesterol entering the cell could in principle
penetrate either directly to the substrate pool for
bile acid synthesis or be esterified by ACAT. If the
route followed in the cell by either free cholesterol
or cholesteryl ester from the lipoprotein leads com-
pulsorily through esterification by ACAT, this
should be detectable by inhibition of this activity
by 58-035. Fig.l shows that the increase in bile acid
synthesis due to the addition of HDL2 is complete¬
ly blocked by the inhibition of ACAT (table 1).
Under the present conditions, therefore, the im¬
mediate fate of the cholesterol taken up by the cells
from HDL2 must be esterification.
This observation is in contrast to our recent ex¬
periments in which the fate of excess cholesterol
newly synthesised from endogenous mevalonate
was studied [9]. Here cholesterol esterification was
stimulated about 2-fold by the addition of
mevalonic acid and bile acid synthesis was also
slightly stimulated. However, in this case 58-035
caused a significant increase in the secretion of bile
acids, implying that excess cholesterol could be
diverted to bile acid synthesis from the ACAT
substrate pool.
It is clearly important in experiments with
hepatocyte monolayers to attempt to correlate
them with the in vivo situation. In the present ex¬
periments HDL2, a specific homologous lipopro¬
tein fraction which carries a substantial amount of
cholesterol in the rat, can deliver cholesterol to the
hepatocyte. This cholesterol follows a defined in¬
tracellular pathway, through ACAT to form the
ester, followed by hydrolysis before it can become
a substrate for bile acid synthesis. The limiting step
in this system is probably the uptake of the
lipoprotein by the cultured cells. This experimental
design represents a close approximation in a
hepatocyte monolayer culture to the situation in
vivo. In our earlier experiments [9] the intracellular
transport and regulatory mechanisms were prob¬
ably saturated by the excess cholesterol synthesised
from the added mevalonate. Uptake mechanisms
were by-passed.
It is possible in cell culture experiments to devise
conditions that will channel cholesterol from dif¬
ferent sources in any desired way. Such control can
be carried out with bovine adrenal cortical cells,
which can use cholesterol from any of several
sources as a substrate for synthesis of Cortisol
[4,6]. Studies such as those reported here show
what pathways are possible for movement of
cholesterol in the cultured cell. Other techniques
would be required to demonstrate the operation of
these pathways in an intact animal.
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